



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07K 14/705, C12N 15/62	A1	(11) International Publication Number: WO 95/04076 (43) International Publication Date: 9 February 1995 (09.02.95)
<p>(21) International Application Number: PCT/US94/08776</p> <p>(22) International Filing Date: 2 August 1994 (02.08.94)</p> <p>(30) Priority Data: 08/100,744 2 August 1993 (02.08.93) US</p> <p>(71) Applicant: CELTRIX PHARMACEUTICALS, INC. [US/US]; 3055 Patrick Henry Drive, Santa Clara, CA 95052-8203 (US).</p> <p>(72) Inventors: MASCARENHAS, Desmond; 27 Maplewood Drive, San Rafael, CA 94901 (US). ZHANG, Yang; 575 E. Remington Drive, 23-I, Sunnyvale, CA 94087 (US). OLSON, Pamela, S.; 18630 Barnhart Avenue, Cupertino, CA 95014 (US). OLSEN, David, R.; 276 Hedge Road, Menlo Park, CA 94025 (US). CARRILLO, Pedro, A.; 1966 California Street #7, San Francisco, CA 94109 (US).</p> <p>(74) Agents: PARK, Freddie, K. et al.; Morrison &amp; Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF THE CYTOPLASM WITHOUT LEADER SEQUENCES</p> <p>(57) Abstract</p> <p>The invention is directed to the use of a fusion partner that does not contain a leader sequence, as a means to increase the solubility and activity of recombinant polypeptides by facilitating the expresssion of fusion proteins, which are then transported out of the cytoplasm. The invention includes a nucleic acid encoding a fusion polypeptide comprising a mature interleukin-1-like polypeptide or a leader-deleted-translocating polypeptide, and a polypeptide of interest; as well as host cells comprising such nucleic acids, and fusion proteins so encoded. The invention also encompasses methods of using such nucleic acids to produce recombinant fusion polypeptides, mature polypeptides of interest, and purified compositions thereof.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

- 1 -

5

EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT  
OF THE CYTOPLASM WITHOUT LEADER SEQUENCES

DESCRIPTION

10

Technical Field

The invention relates to the field of recombinant protein synthesis. In particular, polypeptides of interest are expressed as fusion polypeptides, comprising fusion partners that lack leader sequences, and wherein the fusion partners cause the fusion polypeptides to be secreted from the cytoplasm of host cells.

20 Background Art

Genetic engineering has made it possible to produce large amounts of polypeptides encoded by cloned DNA by means of recombinant expression systems, especially by expression in such prokaryotes as *Escherichia coli* (*E. coli*). The expressed heterologous polypeptide, which would otherwise either not be produced at all by the host cell or be produced only in limited amounts, may constitute a significant proportion of the total cellular polypeptide of the host cell.

30 Several problems are frequently encountered, however. Polypeptides over-expressed in the bacterial cytoplasm often accumulate as insoluble "inclusion bodies" (Williams et al., Science 215:687-688, 1982; Schoner et al., Biotechnology 3:151-154, 1985).  
35 Inclusion body formation is not limited to bacterial expression systems. For example, the Krüppel gene product of *Drosophila* can form inclusion bodies when

-2-

produced in insect cells using a baculovirus expression system. Polypeptides accumulated in the form of inclusion bodies are relatively useless for screening purposes in biological or biochemical assays, or as pharmaceutical agents. Conversion of this insoluble material into active, soluble polypeptide requires slow and difficult solubilization and refolding protocols which often greatly reduce the net yield of biologically active polypeptide.

Even when heterologous polypeptides are expressed in the cytoplasm of bacteria in soluble form, they often accumulate poorly as a result of degradation by host proteases. Further, the accumulated polypeptides often have a different amino terminus than that which is desired.

One approach to these problems is to fuse a polypeptide of interest to a polypeptide fusion partner such as the lacZ and trpE gene products (Goeddel et al., Proc. Natl. Acad. Sci. USA. 76:106-110, 1979; Furman et al. Biotechnology 5:1047-1051, 1987); maltose-binding polypeptide (Di Guan et al., Gene 67:21-30, 1988); glutathione-S-transferase (Johnson, Nature 338:585-587, 1989); ubiquitin (Miller et al., Biotechnology 7:698-704, 1989); or thioredoxin (LaVallie et al., Biotechnology 11:187-193, 1993). Often the fusion partner confers such desirable characteristics as greater solubility on the polypeptide of interest, especially when the recombinant host is cultured at temperatures below the optimum for growth (LaVallie et al., 1993, op. cit.). Low-temperature culture, however, introduces other practical problems which may make the process less suitable on a commercial scale.

The use of polypeptide fusions also allows the production of polypeptides which might otherwise be too



- 3 -

small to accumulate efficiently in the recombinant host (Schultz et al., J. Bacteriol. 169:5385-5392, 1987). Further, appropriate fusion partners may act, e.g., as affinity peptides, facilitating recovery and purification of the fusion polypeptide from cell extracts containing hundreds of other polypeptides (see, e.g., WO 91/11454).

The use of fusion polypeptides has drawbacks, however. It is often necessary to cleave the desired polypeptide away from the fusion partner by enzymatic or chemical means. This can be accomplished by placing an appropriate target sequence for cleavage between that for the fusion partner and for the desired polypeptide.

Unfortunately, the enzymes most widely used for polypeptide cleavage are expensive, inefficient, or imprecise in their cleavage, and cannot always be successfully applied to a majority of fusion constructs. For example, while enterokinase and Factor Xa are highly specific endoproteases, these mammalian enzymes are expensive to produce and require that a polypeptide of interest expressed in a prokaryotic host cell be isolated from the host cell before being treated with the mammalian enzyme, adding considerable expense to a large-scale process. In addition, the efficiency and specificity with which some enzymes cleave substrates is highly variable. While an enzyme like subtilisin, for example, may be relatively inexpensive to produce, the precision with which it cleaves substrates is less than acceptable for commercial-scale processes under current "Good Manufacturing Practices" (GMP).

Some yeast ubiquitin hydrolases efficiently cleave fusions in which ubiquitin is the fusion partner and the amino acid immediately downstream of the cleavage site is not proline (Miller et al., op. cit., 1989; Tobias and Varshavsky, J. Biol. Chem. 266:12021-12028,

- 4 -

1991; see also WO 88/02406 and WO 89/09829). One ubiquitin hydrolase gene cloned from the yeast *Saccharomyces cerevisiae* (*S. cerevisiae*), YUH-1 (Miller et al., op. cit. 1989), will not efficiently cleave fusions in which the downstream polypeptide is larger than about 25 kD. Another *S. cerevisiae* ubiquitin hydrolase gene (Tobias and Varshavsky, J. Biol. Chem. 266:12021-12028, 1991) is capable of cleaving ubiquitin fusions in which the polypeptide downstream of the cleavage site is as large as 130 kD. Both ubiquitin hydrolases are active when expressed intracellularly in *E. coli*, allowing them to be used to cleave fusions *in vivo*. However, the use of ubiquitin as a fusion partner is hampered by the fact that multi-copy plasmids carrying ubiquitin fusion constructs may cause *E. coli* host cells, for example, to grow slowly and lose viability.

Cytoplasmic accumulation of fusion polypeptides suffers from the drawback that the heterologous polypeptide moiety may not be able to fold correctly in the strong reducing environment of the cytoplasm, leading to poor yields of biologically active polypeptide. To overcome this problem the polypeptide of interest may be fused to a "signal peptide", a short (15-30 amino acid) sequence present at the amino terminus of precursor polypeptides destined for secretion, i.e. export to non-cytoplasmic locations. In *E. coli* such locations would include the inner membrane, periplasmic space, cell wall and outer membrane. Typically, at some point just prior to or during transport of polypeptides out of the cytoplasm, the signal sequence is removed by host enzymes to produce the "mature" polypeptide. In these cases in which the signal sequence is removed by host enzymes to produce the "mature" polypeptide, the signal sequences are also known as "leader peptides" (For a recent review

-5-

of the general secretory pathway in gram-negative bacteria and a discussion of leader peptides, see Pugsley, Microbiol. Rev. 57:50-108, 1993).

5           Localization of an expressed polypeptide to the periplasmic space is advantageous because simpler methods of polypeptide recovery can be used, including "osmotic shock" and other techniques. Although leader sequences may be used to deliver heterologous polypeptides into the  
10 periplasmic space of *E. coli*, few polypeptides are efficiently accumulated in soluble form by this method. Translocation of polypeptides across the lipid bilayer of the inner membrane appears to be inefficient, particularly in the case of fusions comprising leader  
15 sequences linked to heterologous polypeptides.

          Only a few polypeptides that naturally lack a leader sequence are secreted to non-cytoplasmic (or periplasmic) locations, as demonstrated by their selective release from cells upon treatment with osmotic  
20 shock or freeze-thaw protocols. These include thioredoxin (Lunn and Pigiet, op. cit., 1982) and elongation factor-Tu (EF-Tu) (Jacobson et al., Biochemistry 15:2297-2302, 1976). IL-1- $\beta$  expressed in *E. coli* has been extracted by a modified osmotic shock  
25 procedure (Joseph-Liauzun et al., op. cit., 1990).

          Extracellular localization may also be advantageous and may be accomplished by at least two different strategies: (1) Permeabilization of the outer membrane, allowing periplasmic polypeptides to "leak" out  
30 (U.S. Patent No. 4,595,658; Kato et al., Gene 54:197-202, 1987); and (2) fusion to sequences which direct extracellular export (Nagahari et al., EMBO J. 4:3589-3592, 1985; U.S. Patent No. 5,143,830). However, these methods do not work in many cases; and even if they  
35 do work, the methods generally are inefficient and often

-6-

do not produce polypeptides with the desired amino terminus (Holland et al., Biochimie 72:131-141, 1990).

5 In the construction of a fusion polypeptide, the ideal fusion partner would be one which is useful for the production of a wide variety of heterologous polypeptides in a recombinant host cell, e.g., *E. coli*, at optimum growth temperatures. Preferably, such a fusion partner would improve the accumulation of the  
10 desired polypeptide in soluble, active form in a cellular location in which it is protected, e.g., from proteolysis, and where the fusion polypeptide may be recovered by simplified procedures. It would also be advantageous if such a fusion partner would allow the use  
15 of an efficient, inexpensive and precise cleavage system *in vivo*.

#### Disclosure of Invention

The present invention is directed to fusion  
20 polypeptides that are selectively transported out from a host cell's cytoplasm comprising a fusion partner that consists essentially of a mature polypeptide or fragment thereof, wherein said fusion partner lacks any leader sequence. Specifically, the invention encompasses fusion  
25 polypeptides comprising: (a) a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like  
30 polypeptides and leader-deleted-translocating polypeptides; and (b) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner. Preferably, the fusion polypeptides of the invention further comprise a  
35 linker peptide positioned between said fusion partner and

- 7 -

said polypeptide of interest. Most preferably, the linker peptide comprises a cleavage site, e.g. one cleaved by ubiquitin hydrolase.

5           The fusion polypeptides of the invention may be produced in a wide variety of host cells, e.g., *E. coli*, in soluble, active, and easily recoverable form at temperatures at or close to the physiological optima for host cell growth. A variety of polypeptides of interest  
10 may be produced in this manner, including enzymes, growth factors, single-chain antibodies, DNA- or RNA-binding proteins, membrane receptors, and fragments thereof.

          Also embodied by the present invention are nucleic acids, preferably expression vectors, encoding  
15 the fusion polypeptides of the invention and host cells comprising such nucleic acids. Preferably, such host cells additionally comprise a nucleic acid capable of expressing in the cytoplasm of the host cell a proteolytic enzyme which specifically recognizes a  
20 cleavage site in the fusion polypeptide, preferably in the linker. Such a system is useful for *in vivo* cleavage of the fusion polypeptides, particularly when ubiquitin hydrolase is co-expressed and cleaves the fusion polypeptide at a compatible cleavage site located within  
25 a linker positioned between the fusion partner and the polypeptide of interest.

          These transformed host cells are useful for the recombinant production of polypeptides of interest as fusion polypeptides, again, preferably using *in vivo*  
30 cleavage to cleave away from the polypeptide of interest other sequences of the fusion polypeptide, e.g., the IL-1-like polypeptide, the leader-deleted-translocating polypeptide, and linker.

          The present invention further embodies methods  
35 of producing substantially purified fusion polypeptides

- 8 -

of the invention that are encoded by a nucleic acid of the invention comprising the steps of: (a) introducing said nucleic acid encoding said fusion polypeptide into a host cell, thereby producing a transformed host cell; (b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide, thereby expressing said fusion polypeptide; and (c) purifying said fusion polypeptide, thereby obtaining a substantially purified fusion polypeptide.

The present invention further embodies methods of producing substantially purified polypeptides of interest comprising the steps of: (a) introducing into a host cell a nucleic acid of the invention encoding one of the fusion polypeptides of the invention which comprises a linker peptide comprising a cleavage site, thereby producing a transformed host cell; (b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide, thereby expressing said fusion polypeptide; (c) cleaving said fusion polypeptide with a proteolytic enzyme or cleavage agent which recognizes said cleavage site, thereby producing said polypeptide of interest; and (d) purifying said polypeptide of interest, thereby obtaining a substantially purified polypeptide of interest.

The present invention further embodies methods of producing substantially purified polypeptides of interest comprising the steps of: (a) introducing into a host cell a nucleic acid of the invention encoding one of the fusion polypeptides of the invention which comprises a linker peptide comprising a cleavage site, wherein said host cell further comprises a nucleic acid capable of expressing in said host cell a proteolytic enzyme which specifically recognizes said cleavage site; thereby producing a transformed host cell; (b) culturing said

-9-

transformed host cell under conditions appropriate for  
expressing said fusion polypeptide and said proteolytic  
enzyme, thereby expressing said fusion polypeptide,  
5 causing the *in vivo* cleavage of said fusion polypeptide,  
and producing said polypeptide of interest; and (c)  
purifying said polypeptide of interest, thereby obtaining  
a substantially purified polypeptide of interest.

The present invention further embodies methods  
10 of producing substantially purified polypeptides of  
interest comprising the steps of: (a) introducing into a  
host cell a nucleic acid of the invention encoding one of  
the fusion polypeptides of the invention which comprises  
a linker peptide comprising a cleavage site, thereby  
15 producing a transformed host cell; (b) culturing said  
transformed host cell under conditions appropriate for  
expressing said fusion polypeptide, thereby expressing  
said fusion polypeptide; (c) purifying said fusion  
polypeptide, thereby producing a substantially purified  
20 fusion polypeptide; (d) cleaving said substantially  
purified fusion polypeptide with a proteolytic enzyme or  
cleavage agent which recognizes said cleavage site,  
thereby producing said polypeptide of interest; and (e)  
purifying said polypeptide of interest, thereby obtaining  
25 a substantially purified polypeptide of interest.

#### Brief Description of Drawings

Figure 1 shows an alignment of the sequences of  
five members of the IL-1-like protein family: (1) *E.*  
30 *coli* DsbA, (2) human IL-1- $\beta$ , (3) human IL-1- $\alpha$ , (4) human  
basic fibroblast growth factor (FGF), and (5) human  
acidic FGF.

Figure 2 summarizes the homologies between the  
mature polypeptides of *E. coli* DsbA, human IL-1- $\beta$ , human  
35 IL-1- $\alpha$ , human basic fibroblast growth factor (FGF), and

-10-

the toxin coregulated pilus (TcpG) polypeptide of *Vibrio cholerae*. The size of each of the mature polypeptides is given in parentheses.

5           Figure 3 shows Coomassie stained SDS-PAGE gels of fractions from *E. coli* cells grown at 37°C in which IL-1- $\beta$  is expressed. A: whole cell lysates ("WCL"), at time 0 (0'); B: WCL, 120 min (120'); C: TEX extract; D: "cytoplasmic" fraction; E: "insoluble" fraction. For  
10 each gel, lane 1 is wild-type IL-1 $\beta$ , lane 2 is IL-1 $\beta$  triple mutant R4A, L6A, R11G, and lane 3 is IL-1 $\beta$  triple mutant R4D L6A R11G. The expected size of wild-type or mutant IL-1 $\beta$  in each case is approximately 17 kD (●).

15           Figure 4 shows SDS-PAGE of fractions from *E. coli* cells expressing *E. coli* DsbA. (a) WCL at 0', 60', and 120' from cells expressing mature DsbA; (b) WCL at 0', 60', and 120' from cells expressing "mutant" DsbA; (c) TEX extract ("T") and "cytoplasmic" ("C") fractions from cells expressing mature DsbA; (d) "T" and "C"  
20 fractions from cells expressing "mutant" DsbA. The expected size of the expressed polypeptide is approximately 22 kD (●).

25           Figure 5 shows SDS-PAGE gels of fractions from *E. coli* cells in which various fusions of IL-1-like proteins with human IGF-I or the soluble extracellular domain of the Type II TGF- $\beta$  receptor were expressed. Left: WCL at 0' and 120' for (1) IL1 $\beta$ -IGF (pDM16963), expected size approximately 24-25 kD; (2) IL1 $\beta$ -Ubi-IGF (pDM16965), expected size approximately 32 kD (●); (3)  
30 DsbA-Ubi-IGF (pYZ22070), expected size approximately 37 kD (●); and (4) DsbA-Ubi-TGFR (pDM15428), expected size approximately 46 kD (●). Right: TEX and "cytoplasmic" ("CYT") fractions for the four fusion polypeptides. Where there are two dots, the lower dot represents a

35



-11-

lower molecular weight breakdown product of the larger polypeptide.

Figure 6 shows SDS-PAGE of fractions from *E. coli* cells expressing human IL-1-receptor antagonist with its natural signal sequence deleted (pDM15424). Left: WCL at 0' and 120'; right, TEX ("T") and "cytoplasmic" ("C") fractions ("FXN"). The expected product has a size of approximately 18 kD.

Figure 7, left, shows SDS-PAGE gels of WCL, 0' and 120', and soluble ("S") and insoluble ("I") fractions from *E. coli* cells transformed with pDJ16920, which encodes ubiquitin-TGF- $\beta$ 2 fusion polypeptide, expected size approximately 20 kD, or plasmid pYZ22096, which encodes a DsbA-ubiquitin-TGF- $\beta$ 2 fusion, expected size approximately 42 kD.

Figure 8, left: SDS-PAGE gels of WCL, 0' and 120' and soluble ("S") and insoluble ("I") fractions from *E. coli* cells transformed with pDJ16927, which expresses a ubiquitin-IGF fusion, expected size of about 15 kD, or with pDM16965, which expresses IL-1- $\beta$ -ubiquitin-IGF, expected size approximately 32 kD. Figure 8, right shows similar gels of extracts of *E. coli* cells transformed with pYZ22070, which encodes DsbA-ubiquitin-IGF, with an expected size of approximately 37 kD, or with pDM15426, which encodes DsbA-ubiquitin-IGF in which DsbA has its native signal sequence, expected size of about 37 kD.

Figure 9 shows SDS-PAGE gels of fractions of *E. coli* cells expressing fusions to IGFBP-3. Panel [i]: WCL at 0' and 120' and "soluble" ("S") and "insoluble" ("I") extracts of *E. coli* cells expressing pDJ12875, which encodes a ubiquitin-IGFBP-3 fusion having an expected size approximately 38 kD; panel [ii], IL-1-ubiquitin-IGFBP-3 having an expected size of approximately 55 kD

-12-

(pDM16967); and [iii], DsbA-ubiquitin-IGFBP-3 having an expected size of approximately 60 kD (pDM15427).

5 Figure 10, panel [i], shows SDS-PAGE gels of WCL at 0' and 120' and "soluble" ("S") and "insoluble" ("I") fractions from *E. coli* cells expressing a ubiquitin-TGF- $\beta$ R fusion with an expected size of approximately 24 kD (pDJ16921); panel [ii], a DsbA-ubiquitin-TGF- $\beta$ R fusion with an expected size of approximately 46 kD (pDM15428).

10 Figure 11A and B: HPLC-reverse phase elution profiles from ubiquitin hydrolase-cleaved IGF-I derived from cultures of DsbA-ubiquitin-IGF and ubiquitin-IGF constructs, respectively, grown at 30°C. C and D: ubiquitin hydrolase-cleaved DsbA-ubiquitin-IGF and ubiquitin-IGF, respectively, grown at 37°C. The specific activity of the IGF peaks is shown as boxed values, arbitrary units).

20 Figure 12 shows SDS-PAGE gels of partially purified TGF- $\beta$ R (136 amino acid extracellular domain, pDM15428) cross-linked with  $^{125}$ I-radiolabeled TGF- $\beta$ 1. The size of the expected cross-linked product is approximately 30 kD. Left (-): no added cold TGF- $\beta$ 1. Right (+): excess cold TGF- $\beta$ 1 (2500-fold molar).

25 Figure 13 shows results of dot-blot assays using  $^{125}$ I-radiolabeled IGF-I to measure binding activity in crude extracts ("soluble" fraction) of *E. coli* cells expressing (1) pDM15427, which encodes a DsbA-ubiquitin-IGFBP-3 fusion; (2) pDJ12875, which encodes a ubiquitin-IGFBP-3 fusion; or (3) pDJ12887, a "vector only" control. Samples were untreated (-UH) or cleaved with ubiquitin hydrolase (+UH).

35 Figure 14 shows SDS-PAGE gels of cross-linked samples from COS cells transiently transfected pDM15430, which encodes IL-1- $\beta$ -IGFBP-3 ("IL1-BP3") or the vector

-13-

alone ("vector"), with (+) or without (-) treatment of the crosslinked sample with endoglycosidase F, and with or without competition with "cold" IGF. On the right side of the figure are labels for the 55 kD fusion polypeptide (X), a native, glycosylated IGF binding protein (Y) and the native, deglycosylated IGF binding protein (Z).

Figure 15 shows the proteins expressed by plasmids pDM15486, pDM25492, pDM46805 and pDM46806 when they are introduced into W3110DE3. Panels "A" and "B" of Figure 15 show the TEX extracts (T) and the remaining soluble fraction (S) after sonication of strains carrying pDM25492 and pDM46805 respectively. The corresponding samples for the IGF-I fusion constructs, pDM15486 and pDM46806, are shown in panels "C" and "D" of Figure 15. The expected position of the DsbC protein is marked by an arrow in each case.

Figure 16 shows the proteins expressed by plasmids pDM15486, pDM25492, pDM46805 and pDM46806 when they are tested as described for the constructs in Example 10 above. Panels "A" and "B" show a comparison of pYZ9206 (leader-deleted DsbA) and pDM25452 (leader-deleted mini-DsbA). In each case the induced samples have been fractionated into TEX (T), remainder soluble (S), and insoluble (I) fractions. Panel "C" shows the results obtained with pDM25499.

Figure 17 shows the results obtained when the proteins expressed by plasmids pYZ22055, pDM25450, pDM25453 and pDM15449 are analyzed. Lanes "A", "B", "C" and "D" in each panel were loaded with extracts corresponding to pYZ22055, pDM25450, pDM15449 and pDM15457. The two constructs expressing the 13-mer biotinylation substrate peptide (pDM25450 and pDM15457)

-14-

provide clear positive signals on the Western blot, whereas the controls do not.

5 Figure 18 shows the fractionation of samples taken from induced cells carrying pDM15449 (panels "A") or pDM25466 (panels "B").

Figure 19A shows the expression of the fusion protein and its partial fractionation into TEX (T) and remainder soluble (S) fractions.

10 Figure 19B shows that both purified fractions show DNA-binding activity.

Figure 20 shows the nucleic acid sequence for native dsbA (with leader)-biotinylation peptide (Plasmid 25453).

15 Figure 21 shows the nucleic acid sequence for leaderless dsbA (3'modified)-biotinylation peptide (Plasmid 25450).

20 Figure 22 shows the nucleic acid sequence for leaderless dsbA (3'modified)-hubi(del45).IGF.new (Plasmid 25477).

Figure 23 shows the nucleic acid sequence for leaderless dsbA (3'modified)-hubi.IGF.new (Plasmid 41620).

25 Figure 24 shows the nucleic acid sequence for native dsbA (Plasmid 9205).

Figure 25 shows the nucleic acid sequence for leaderless dsbC (3'modified)C>S variant (Plasmid 46805).

Figure 26 shows the nucleic acid sequence for leaderless dsbA (Plasmid 9206).

30 Figure 27 shows the nucleic acid sequence for leaderless dsbA (3'modified) (Plasmid 22055).

Figure 28 shows the nucleic acid sequence for leaderless mini-dsbA (3'modified) (Plasmid 25452).

35

-15-

Figure 29 shows the nucleic acid sequence for leaderless dsbA (3'modified)-y.ubi.IGF.old (Plasmid 22070).

5        Figure 30 shows the nucleic acid sequence for leaderless dsbC (3'modified)-hubi.IGF.new (Plasmid 25498) (Vector pUC18).

10       Figure 31 shows the nucleic acid sequence for leaderless dsbC (3'modified)C>S variant-IGF1(new) (Plasmid 46806).

Figure 32 shows the nucleic acid sequence for leaderless dsbC (3'modified)-IGF1(new) (Plasmid 15486).

Figure 33 shows the nucleic acid sequence for leaderless dsbC (3'modified) (Plasmid 25492).

15       Figure 34 shows the nucleic acid sequence for mature human interleukin 1 beta (3'modified)-IGF(old) (Plasmid 16963) (Vector pBR322).

20       Figure 35 shows the nucleic acid sequence for mature human interleukin 1 beta (Plasmid 12151) (Vector pBR322).

Figure 36 shows the nucleic acid sequence for mature human interleukin 1 beta (3'modified) (Plasmid 15449).

25       Figure 37 shows the nucleic acid sequence for human interleukin 1 beta R11G mutant (3'modified) (Plasmid 25466).

Figure 38 shows the nucleic acid sequence for interleukin-1 receptor antagonist (3'modified)-IGF(new).

30       Figure 39 shows the nucleic acid sequence for leaderless interleukin-1 receptor antagonist (3'modified) (Plasmid 15424).

Figure 40 shows the nucleic acid sequence for mature human interleukin 1 beta (3'modified)-yubi.IGF.old (Plasmid 16965).

35

-16-

Figure 41 shows the nucleic acid sequence for mini-dsba (3'modified)-hubi(del145).IGF.new (Plasmid 25499).

5           Figure 42 shows the nucleic acid sequence for leaderless mini-dsba (3'modified)-hubi.IGF.new (Plasmid 25485) (Vector pUC18).

#### Modes for Carrying out the Invention

10           A wide range of polypeptides, when fused to a fusion partner comprising an interleukin-1-like polypeptide ("IL-1-like polypeptide"), a leader-deleted-translocating polypeptide, or fragments thereof, accumulate in large quantities in soluble, active, easily  
15           recoverable form in a variety of host cells at temperatures close to or at the physiological optima for host cell growth. If desired, the polypeptide of  
20           interest may be cleaved away from the interleukin-1-like polypeptide efficiently and inexpensively either *in vivo* or *in vitro*. Both interleukin-1-like polypeptides and leader-deleted-translocating polypeptides are useful as generic fusion partners for the expression of a wide variety of heterologous polypeptides in both prokaryotic and eukaryotic cells, including *E. coli*, yeast, insect  
25           cells and mammalian cells.

            Interleukin-1- $\beta$  (IL-1- $\beta$ ) is one of a unique class of naturally secreted polypeptides which lack signal sequences (Muesch et al., TIBS, March 1990, pp. 86-88, 1990). Members of this class may be found in a  
30           wide range of species, from bacteria to humans. In mammalian monocytes IL-1- $\beta$  transport out of the cytoplasm has been shown to be independent of the general secretory pathway (Rubartelli et al., EMBO J. 9:1503-1510, 1990; Singer et al., J. Exp. Med. 167:389-407, 1988; see also  
35           Rubartelli et al., J. Biol. Chem. 267:24161-24164, 1992).

-17-

Although IL-1- $\beta$  does not contain an amino-terminal signal peptide or a significant hydrophobic region which could function as an internal signal sequence, when the gene for IL-1- $\beta$  is expressed in *E. coli* host cells, the IL-1- $\beta$  polypeptide can be released from the host cells by osmotic shock without lysing the cells (Joseph-Liauzun et al., Gene 86:291-295, 1990). Moreover, IL-1- $\beta$  containing an amino-terminal methionine (Met-IL-1- $\beta$ ) is secreted by yeast cells (G.P. Livi, personal communication, reported in Joseph-Liauzun et al., op. cit., 1990).

It is believed that in mammalian monocytes IL-1 interacts with the cytoplasmic membrane, forms vesicles and is secreted without passing through the endoplasmic reticulum (ER) or Golgi apparatus. Because of this property, consensus glycosylation sites on the polypeptide remain unglycosylated. However, glycosylation of IL-1- $\beta$  does occur if a cleavable signal sequence is attached to its amino terminus (Baldari et al., EMBO J. 6:229-234, 1987). The use of IL-1-like polypeptides as fusion partners can therefore permit production of nonglycosylated polypeptides in mammalian cells. This feature will be especially important in cases in which the glycosylation of a polypeptide of interest would be undesirable. For example, when human proteins are synthesized in other mammalian cells, different glycosylation may occur and may be antigenic to human recipients. This is a major area of concern for those interested in expressing polypeptides useful as human therapeutics in such transgenic animals as goats or sheep.

Moreover, since the alternative route of transport out of the cytoplasm employed by IL-1-like polypeptides avoids the ER, it may be advantageous to

-18-

express polypeptides with free sulfhydryl groups, e.g., bFGF, PD-ECGF, and ADF (Takahashi et al., Proc. Natl. Acad. Sci. USA. 83:8019-8023, 1986), as fusions to IL-1-like polypeptides because IL-1-like fusions avoid the oxidizing milieu of the ER lumen.

Also, IL-1-like fusions appear to be secreted without translocation across a lipid bilayer. Thus, using IL-1-like fusions with heterologous polypeptides which cannot normally be secreted via the general secretory pathway now permits the successful transport out of the cytoplasm of those polypeptides. Examples include but are not limited to polypeptides containing long hydrophobic or other sequences which can interfere with passage through the lipid bilayer.

For the purposes of the present invention, an "interleukin-1-like" (or "IL-1-like") polypeptide is a polypeptide or functional fragment thereof which may be characterized by a three-dimensional structure substantially similar to that of mature human interleukin-1- $\beta$  (Priestle et al., Proc. Natl. Acad. Sci. USA. 86:9667-9671, 1989) . When fused to a polypeptide of interest, such an IL-1-like polypeptide is also capable of directing the transport out of the cytoplasm of that fusion polypeptide into a privileged cellular compartment in which the fusion polypeptide is soluble and biologically active but is protected from proteolysis.

In nature, mature IL-1- $\beta$  is relatively small (about 17 kD) and stable. It is synthesized as a large inactive precursor which is later cleaved to release a mature polypeptide 153 amino acids long. Mature IL-1- $\beta$  possesses a uniquely stable structure -- a so-called beta-trefoil fold -- characterized by three similar units arranged around a three-fold axis of symmetry to form a



-19-

barrel structure, each unit containing two pairs of antiparallel beta strands (Priestle et al., op. cit., 1989). This beta-trefoil fold, a structure which contains no alpha helices, may serve to stabilize the overall structure of a fusion polypeptide of which it is a part. Members of the beta-trefoil structural family include but are not limited to the following: IL-1- $\alpha$  and IL-1- $\beta$ ; members of the fibroblast growth factor (FGF) family including, e.g., acidic FGF and basic FGF, int-2, hst/KS3, FGF-5, FGF-6, and keratinocyte growth factor (Zhang et al., Proc. Natl. Acad. Sci. USA. 88:3446-3450, 1991; Zhu et al., Science 251:90-93, 1991); hisactophilin (Habazettl et al., Nature 359:855-857, 1992); and soybean trypsin inhibitor (Wolfson et al., Biochemistry 32:5327-5331, 1993). See also McDonald and Hendrickson, Cell 73:421-424, 1993.

Polypeptides which share the beta-trefoil structure will be considered IL-1-like polypeptides if, like IL-1, they are capable of directing the transport out of the cytoplasm of a fused polypeptide of interest into a privileged cellular compartment from which it can readily be released in active form, e.g., by a selective extraction procedure. Thus, the presence of a beta-trefoil structure may be used to demonstrate that a potential fusion partner is an interleukin-1-like polypeptide. For example, basic FGF, which lacks a leader sequence, is known to be secreted from cells by a process similar to that for IL-1- $\beta$  (Abraham et al., Science 233:545-548, 1986).

"IL-1-like polypeptides" include only mature polypeptides and functional fragments thereof, which: (a) lack an amino-terminal leader sequence recognizable by the method of von Heijne (Nucl. Acids. Res. 14:4683-4690, 1986); (b) have an amino acid sequence that is at least

-20-

20% homologous with the amino acid sequence of mature human interleukin-1- $\beta$  (IL-1- $\beta$ ) when optimally aligned; and (c) are capable of directing the translocation of greater than about 20% of a fusion polypeptide into a privileged cellular compartment. Where an IL-1-like polypeptide is naturally synthesized as a precursor with an amino-terminal leader sequence, only the DNA sequence corresponding to the mature polypeptide, i.e., lacking a leader sequence, is considered the nucleic acid encoding the "IL-1-like polypeptide" for the purposes of the present invention. Thus, the "IL-1-like polypeptides" of the present invention include the members of the interleukin-1 gene family, which includes interleukin-1- $\alpha$  and - $\beta$  and the interleukin-1 receptor antagonist (IL-1ra) from human and nonhuman species, e.g., mouse and rat, (Eisenberg et al., Nature 343:341-346, 1990; Eisenberg et al., Proc. Natl. Acad. Sci. USA. 88:5232-5236, 1991), as well as DsbA from *E. coli* and related bacteria.

The mature *E. coli* DsbA polypeptide (Bardwell et al., Cell 67:581-589, 1991; Kamitani et al., EMBO J. 11:57-62, 1992) and its known bacterial homologs (including *Vibrio cholerae* TcpG; Peek and Taylor, Proc. Natl. Acad. Sci. USA. 89:6210-6214, 1992) are also examples of IL-1-like polypeptides by these criteria. DsbA is normally secreted to the periplasmic space, presumably with the aid of an amino-terminal leader sequence of 19 amino acids which is removed during translocation. However, a DsbA polypeptide variant in which the leader peptide is replaced by a single methionine displays unexpected behavior: Not only does the polypeptide cross the cell membrane, but transport across the membrane is actually increased. DsbA also can be released from cells by a modified osmotic shock

-21-

procedure and other simplified methods which do not lyse the cell, as is shown in the Examples below.

Figure 1 shows the sequence similarity between human IL-1- $\beta$  DNA and the truncated dsbA gene. To maximize alignment, two regions of the dsbA sequence (corresponding to amino acid residues 21-35 and 126-157) are excluded from the comparison. The first of these segments (21-35) contains an example of a "double cysteine active site loop domain" which exhibits partial homology to the active site regions of other oxidoreductases (Bardwell et al., op. cit., 1991). This region of homology is absent from the other classes of IL-1-like polypeptides, suggesting that this region is not necessary for the properties of the IL-1-like polypeptides of the present invention. These double cysteine active site loop domains, e.g., the domain contained within residues 21-35 of DsbA, may be removed (or replaced) from fusion partners comprising any of the oxidoreductases that fall into the interleukin-1-like polypeptide or leader-deleted-translocating polypeptide classes and may not affect transport of a fusion polypeptide of the invention.

It should be noted that the term "interleukin" embraces a large number of proteins -- 26 to date -- which vary widely in terms of sequence homology and structure. Interleukins other than IL-1 would generally not be considered "IL-1-like polypeptides" as defined above.

Thioredoxin is not considered an IL-1-like polypeptide. Thioredoxin secretion is similar in certain aspects to that of the IL-1-like polypeptides in that *E. coli* thioredoxin lacks a leader sequence and mammalian thioredoxin appears to be secreted without engaging the ER and Golgi apparatus. However, there is less than 15%

-22-

sequence homology between IL-1 and thioredoxin, and there is no obvious similarity in their three-dimensional structures. Moreover, the secretion of IL-1- $\beta$  differs from that of thioredoxin. For example, COS transfectants secrete thioredoxin but not IL-1- $\beta$ . Moreover, in activated monocytes, some IL-1- $\beta$  is found within intracellular vesicles, while the thioredoxin is not detected in membrane-bound compartments such as vesicles, suggesting that secreted thioredoxin molecules translocate directly to the plasma membrane (Rubartelli et al., op. cit., 1992). Thioredoxin preferentially resides at sites around the inner periphery of the cytoplasmic membrane in *E. coli* as adhesion zones, or Bayer's patches (sites at which there are gaps in the peptidoglycan cell wall where the inner and outer cell membranes are fused together). These observed differences in secretion between IL-1- $\beta$  and thioredoxin indicate that these two polypeptides may employ different secretory pathways.

LaVallie et al. (op. cit., 1993) have proposed the use of thioredoxin as a fusion partner, although some thioredoxin fusions become more soluble as the growth temperature of cells expressing them is lowered (LaVallie et al., op. cit., 1993).

"Leader-deleted-translocating polypeptides" include only mature polypeptides and functional fragments thereof, which: (a) are derived from proteins which in their native states comprise amino-terminal leader sequences when first translated, wherein the amino-terminal leader sequences are subsequently cleaved in the formation of the mature proteins; and (b) are capable of directing the translocation of greater than about 20% of a fusion polypeptide into a privileged cellular compartment. While all proteins from which

-24-

from multiple IL-1-like polypeptides, multiple leader-deleted-translocating polypeptides, or a combination of fragments derived from both classes of polypeptides is specifically contemplated in the present invention. In addition, the present invention specifically includes the use of mutant IL-1-like polypeptides or mutant leader-deleted-translocating polypeptides in the fusion partners of the fusion polypeptides of the invention. Such mutations may include deletions, the exchange of amino acids, or the addition of amino acids, particularly mutant polypeptide fragments of mature interleukin-1- $\beta$  that are "defective with respect to interleukin-1- $\beta$  biological activity" (having less than 3% of wild type interleukin-1- $\beta$  biological activity).

Fusion polypeptides comprising the DNA sequence of an IL-1-like polypeptide or leader-deleted-translocating polypeptide fused to the DNA of a selected heterologous polypeptide, or any peptide of interest, may be readily constructed by conventional genetic engineering techniques. The IL-1-like polypeptide is preferably fused to the amino terminus of a selected heterologous polypeptide, although insertion of the selected polypeptide into a site within an IL-1-like polypeptide may also be appropriate. For example, heterologous polypeptidase inhibitor loops have been inserted into IL-1- $\beta$  at an internal site. See Wolfson et al., op. cit., 1993.

The nucleic acid encoding the fusion polypeptide may optionally contain, in addition to the fusion partner comprising IL-1-like polypeptide or leader-deleted-translocating polypeptide, and the polypeptide of interest, additional "linker" DNA encoding additional amino acids. The linker peptide is positioned between the fusion partner and the peptide of interest.

-25-

A linker peptide may serve a number of functions. First, a linker may provide a specific cleavage site between the IL-1-like polypeptide and the polypeptide of interest. Such a cleavage site may contain a target for a proteolytic enzyme such as, for example, Factor Xa, trypsin, collagenase, thrombin, or subtilisin enterokinase, or, preferably, ubiquitin hydrolase; or for such chemical "cleavage agents" as, for example, cyanogen bromide, or hydroxylamine.

The cleaving steps can be performed *in vivo* by a proteolytic enzyme which is expressed by the host cell and specifically recognizes the proteolytic cleavage site of the linker peptide. Alternatively cleaving steps can be performed on fusion polypeptide samples with or without a prior purification step to remove host cell material, and followed by a purification step to remove the cleavage agent or proteolytic enzyme, and cleaved protein fragments, e.g., fusion partners and linkers. The methods for cleaving the peptide of interest from the fusion proteins of the invention, and the various related purification steps are specific to the cleavage agent or proteolytic enzyme used, and are known in the art. Examples of appropriate methods of cleaving steps and purification steps are described below and exemplified in the Examples section below.

A linker may also encode an "affinity tag" to aid in the purification of the fusion polypeptide away from other cellular polypeptides. For example, multiple histidine residues encoded by the linker allow the use of metal chelate affinity chromatography methods for purification of the fusion polypeptide.

The linker may also serve as a spacer, e.g., to prevent steric hindrance in a fusion polypeptide between the IL-1-like polypeptide and the polypeptide of

-26-

interest. Whether a linker is necessary will depend upon the structural and functional characteristics of the polypeptide of interest to be fused to an IL-1-like polypeptide, as will be apparent to those skilled in the art. If the polypeptide of interest is naturally cleaved, no linker may be necessary. The fusion polypeptide itself may be useful without cleavage.

The linker may serve any or all of these purposes or additional functions, or other functions as desired.

The ability of the IL-1-like polypeptide or leader-deleted-translocating polypeptide to target a fusion polypeptide to an extracytoplasmic space in the presence of other sequences within the same host cell (e.g., after permeabilization of the outer membrane, allowing periplasmic polypeptides to "leak" out, as taught in U.S. Patent No. 4,595,658) simplifies the purification of the fusion polypeptide, since *E. coli*, for example, secretes few polypeptides to the culture medium. Alternatively, simply treating whole cells expressing the fusion polypeptide with appropriate extraction buffers, as shown in the Examples below, can selectively release the fusion polypeptide without releasing the majority of cytoplasmic polypeptides or nucleic acids. Such selective release greatly simplifies purification of the fusion polypeptide.

A wide variety of polypeptides, including those which are otherwise unstable or largely insoluble, may be expressed as fusions with the IL-1-like polypeptides or leader-deleted-translocating polypeptides of the present invention in prokaryotic or eukaryotic cells by employing appropriate expression systems.

In brief, the present invention provides methods and compositions in which a nucleic acid

-27-

comprising sequences encoding an IL-1-like-polypeptide or leader-deleted-translocating polypeptide are fused to a polypeptide of interest, preferably in an expression vector. In the Examples, a T7 RNA polymerase-driven expression system (Studier and Moffat, J. Mol. Biol. 189:113-130, 1986), modified by translational coupling (Squires et al., J. Biol. Chem. 263:16297-16302, 1988), has been utilized to express large quantities of fusion polypeptides in which an IL-1-like polypeptide sequence is attached to the amino terminus of a heterologous polypeptide via a linker polypeptide sequence. Several examples of heterologous polypeptides have been used to show the generic properties of this expression system, including two growth factors, two enzymes, a single-chain antibody, a binding polypeptide and the extracellular domain of a membrane-spanning receptor. The Examples show that the methods and compositions of the present invention enable the high-level soluble expression of certain desirable therapeutic polypeptides, e.g. IGF-I, which are otherwise produced at low levels in bacterial host cells.

The production of fusion polypeptides according to this invention reliably improves the solubility of desired heterologous polypeptides and, by promoting the folding of the desired polypeptides into active conformations and sequestering the fusion polypeptides into a privileged compartment inside the host cell or causing transport out of the cytoplasm of the host cell, enhances the stability and accumulation of the heterologous polypeptide products.

Further, the present invention permits the screening of libraries of random polypeptides by assays for their biological function. When fused to an IL-1-like polypeptide, the random polypeptides accumulate in a



-28-

protected cellular compartment in a soluble, active form. Functional screening of expression libraries containing mammalian DNA has been hampered by the fact that there is  
5 no assurance that the desired protein's function is maintained. This problem can easily be obviated by cloning the gene sequences of the library into an expression vector including a sequence for an IL-1-like polypeptide so that the library sequences can be  
10 expressed as IL-1 fusions. For example, colonies of *E. coli* cells transformed with the library are transferred to a solid support such as a nylon membrane. There the cells are gently lysed (e.g., using a mild detergent such as Triton-X 100) to release the expressed fusion  
15 polypeptides, and the fusion polypeptides are screened for biological activity which identifies the clone with the gene of interest.

Additionally, the fusion polypeptides of the present invention may be used to develop antibodies, including monoclonal antibodies, by well known methods  
20 familiar to those skilled in the art.

#### Polypeptides

Ordinarily, the IL-1-like polypeptides of the present invention are at least about 20% homologous to  
25 the native human IL-1- $\beta$  polypeptide, preferably at least 40-60%, and more preferably at least about 95% homologous. Such homology is considered to be "substantial homology," although the common possession of  
30 the three-dimensional structure characteristic of IL-1, while not required, may be used to identify and IL-1-like polypeptide.

Polypeptide homology is typically analyzed using sequence analysis software such as the Sequence  
35 Analysis Software Package of the Genetics Computer Group,

-29-

University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, WI 53705). Polypeptide analysis software matches similar sequences using measures of homology assigned to various substitutions, deletions, substitutions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

A "fragment" of an IL-1-like polypeptide or a leader-deleted-translocating polypeptide is a portion of a full length IL-1-like or leader-deleted-translocating polypeptide which substantially retains its functional characteristics. That is, an IL-1-like polypeptide fragment or leader-deleted-translocating polypeptide fragment is one capable of directing the translocation of at least about 20% of a fusion polypeptide to an appropriate privileged cellular compartment of the host cell in which it is expressed. Also the phrase "capable of directing extracytoplasmic transport" is used to mean that the polypeptide or fragment so described is one that is capable of being targeted to an appropriate protected cellular compartment of the host cell in which it is expressed.

In addition, The terms "leader peptide", "signal peptide", and "leader" are used interchangeably herein to mean short (15-30 amino acid) sequences present at the amino terminus of precursor polypeptides destined for secretion, i.e. export to non-cytoplasmic locations, which are not present in mature proteins.

"Isolated" The terms "isolated," "substantially pure," "substantially purified," and "substantially homogeneous" are used interchangeably to

-30-

describe a polypeptide which has been separated from its natural components including, for example, a linker sequence, etc., which has been chemically or enzymatically cleaved in order to obtain the polypeptide of interest without such components. A monomeric polypeptide is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises about 60 to 90% W/W of a polypeptide sample, more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a polypeptide sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

Polypeptide purification When expressed in bacterial cells, fusion polypeptides comprising an IL-1-like polypeptide or leader-deleted-translocating polypeptide moiety may be released from the cells by modified osmotic shock, freeze/thaw procedures, or by resuspension in certain extraction buffers, as exemplified below. Further polypeptide purification can be accomplished by various methods well known in the art, e.g., affinity chromatography.

It may be advantageous to cleave the fusion polypeptide in order to isolate a polypeptide of interest away from a fusion partner and/or linker sequence or other sequences comprising the fusion polypeptide of which it is a part. A linker comprising a sequence encoding a polyhistidine stretch, for example, can be purified by binding to a resin such as Ni-NTA resin (QIAGEN, Chatsworth, CA) and ProBond resin (Invitrogen,

- 31 -

San Diego, CA). Other useful methods of polypeptide purification are described, e.g., in Guide to Polypeptide Purification, ed. M. Deutscher, 182 Meth. Enzymol.

5 (Academic Press, Inc.: San Diego, 1990) and R. Scopes, Polypeptide Purification: Principles and Practice, Springer-Verlag: New York, 1982.

10 Preferably, cleavage of the fusion polypeptide occurs *in vivo* via the co-expression of a compatible proteolytic enzyme in the cytoplasm of the host cell. In bacterial hosts such as *E. coli*, ubiquitin hydrolase is preferred. When expressed along with a polypeptide having a ubiquitin hydrolase cleavage site, e.g., as part of a linker in the fusion genes of the present invention, 15 ubiquitin hydrolase cleaves specifically and efficiently, as demonstrated in Example 6.

The intact fusion polypeptide may also be useful. For example, a fusion of human interleukin-1- $\beta$ , or its analogues, to a second polypeptide may have 20 therapeutic uses.

Polypeptide modifications; fragments; fusion polypeptides The present invention also provides for polypeptides or fragments thereof which are substantially homologous to the primary structural sequence of the 25 human IL-1- $\beta$  polypeptide. The present invention also embraces polypeptides with *in vivo* or *in vitro* chemical and biochemical modifications or which incorporate unusual amino acids. Such modifications are well known and include, for example, acetylation, carboxylation, 30 phosphorylation, glycosylation, ubiquitination, labelling, e.g., with radionuclides, various enzymatic modifications. See, e.g., Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, ed. Sambrook, et al., Cold Spring Harbor Laboratory Press (1989) or 35 Current Protocols in Molecular Biology, ed. F. Ausubel et

- 32 -

al., Greene Publishing and Wiley-Interscience: New York (1987 and periodic updates).

5 The present invention provides fusion polypeptides comprising an IL-1-like polypeptide or leader-deleted-translocating polypeptide, and any polypeptide of interest. Examples of polypeptides fused to an IL-1-like polypeptide or leader-deleted-translocating polypeptide include any peptide or  
10 polypeptide useful for human or veterinary therapy, diagnostic or research applications. Such polypeptides of interest include but are not limited to hormones, cytokines, growth or inhibitory factors, and enzymes.

15 The IL-1-like polypeptides, leader-deleted-translocating polypeptides, polypeptides of interest and fusion polypeptides are typically made by recombinant methods but may be chemically synthesized. Techniques for synthesis of polypeptides are described, for example, in Merrifield, J. Amer. Chem. Soc. 85:2149-2156, 1963.

20

#### Nucleic Acids

The present invention provides nucleic acids which encode a fusion polypeptide comprising an IL-1-like polypeptide or a leader-deleted-translocating  
25 polypeptide, and another polypeptide of interest. Such nucleic acids include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands. Such nucleic acids can be chemically or biochemically modified and can contain non-natural or derivatized nucleotide bases. The sequence encoding the  
30 fusion polypeptide can be interrupted by introns.

The nucleic acid sequences of this invention are of a length sufficient to encode such a fusion polypeptide and, if necessary, any vector sequences. The  
35 sequences are usually several hundred nucleotides or

-33-

nucleotide base pairs in length and may be several kilobases long.

Techniques for nucleic acid manipulation, including the construction of nucleic acids capable of encoding and expressing the fusion polypeptides of the present invention, are well known and are described generally, for example, in Sambrook et al., op. cit., or Ausubel et al., op. cit. Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available.

The recombinant nucleic acid sequences used to produce fusion polypeptides of the present invention may be derived from natural or synthetic sequences. The nucleotide sequences and amino acid sequences and/or fragments thereof may be obtained from GENBANK and/or the Swiss Protein Database, with the database accession numbers as follows:

20

25

30

35

-34-

	<u>Gene</u>	<u>GENBANK</u>	<u>Swiss-Prot</u>
	IGF	HUMIGFI SYNHUMGFIS	
5	ubiquitin	YSCUBI1G YSCUBI2G YSCUBI3G YSCUBI4G	UBIQ_YEAST
	ubiquitin hydrolase	YSCUBP1	
10	IL-1- $\beta$	HUMIL1AA	IL1B_HUMAN
	IL-1-RA	HSI1RA	
	IL-1- $\alpha$	HUMIL1AA AGHSIL1A	
	<u>Gene</u>	<u>GENBANK</u>	<u>Swiss-Prot</u>
15	FGF- $\beta$	HUMFGFB	
	TGF- $\beta$		TGF2_HUMAN
	TGF- $\beta$ -receptor II	HUMTGFBIIIR	
	IGFBP-3		IBP3_HUMAN
20	TcpG	VCDSBAG	
	<u>EGF-binding kallikrein</u>	<u>MUSEGFBPB</u>	

In the case of IGF and IGFBP-3, codon-optimized genes were employed. In all cases only the portions of each sequence coding for the mature gene product were used.

The nucleotide sequences of various IL-1-like and leader-deleted-translocating polypeptides have also been reported, e.g., in: Maliszewski et al., Mol. Immunol. 25:429-437, 1988; Auron et al., Proc. Natl. Acad. Sci. USA. 81:7907-7911, 1984; March et al., Nature (Lond.) 315:641-647, 1985; Lomedico et al., Nature (Lond.) 312:458-462, 1984; Gray et al., J. Immunol. 137:3644-3648, 1986; Nishida et al. in Monokines and Other Nonlymphocytic Cytokines, eds. Powanda et al. (Liss, New York), pp. 73-78, 1988; Furutani et al., Nucl.

-35-

5 Acids Res. 13:5869-5882, 1985; Mori et al., Biochem.  
Biophys. Res. Commun. 150:1237-1243, 1988 (IL-1- $\alpha$  and IL-  
1- $\beta$  from human, mouse, rat, bovine and rabbit); Eisenberg  
et al., Proc. Natl. Acad. Sci. USA. 88:5232-5236, 1991  
10 (human, mouse, and rat IL-1ra); and Bardwell et al., Cell  
67:581-589, 1991 (E. coli DsbA); Lovett and Kolodner, J.  
Bacteriol. 173:353-364, 1991; Missiakas et al., EMBO J.  
13:2013-2020, 1994 (DsbC). These references are  
10 incorporated by reference herein.

Other sequences employed in the construction of  
the fusion polypeptides of the present invention include  
the soluble extracellular domain of the Type II TGF- $\beta$   
receptor (Lin et al., Cell 68:775-785, 1992) and EGF-  
15 binding kallikrein (Blaber et al., Biochemistry 26:6742-  
6749, 1987). Any expression vector compatible with a  
chosen host cell may be employed in the practice of the  
present invention.

Construction of the fusion polypeptides of the  
present invention is readily accomplished using well  
20 known methods in recombinant DNA technology, e.g., PCR,  
automated DNA synthesis, etc.

"Encode" A nucleic acid is said to "encode" a  
polypeptide if, in its native state or when manipulated  
25 by methods well known to those skilled in the art, it can  
be transcribed and/or translated to produce the  
polypeptide. The anti-sense strand of such a nucleic  
acid is also said to encode the polypeptide.

"Operably linked" A nucleic acid sequence is  
30 operably linked when it is in a functional relationship  
with another nucleic acid sequence. For instance, a  
promoter is operably linked to a coding sequence if the  
promoter affects its transcription or expression.  
Generally, operably linked means that the DNA sequences  
35 being linked are contiguous and, where necessary to join



-36-

two polypeptide coding regions, contiguous and in reading frame.

5       "Recombinant" The term "recombinant" nucleic acid (and by analogy, a "recombinant" polypeptide produced by the expression of a recombinant nucleic acid) is one which is not naturally occurring or is made by the artificial combination of two otherwise separated segments of sequence by chemical synthesis means or the  
10       artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

Preparation of recombinant or chemically synthesized nucleic acids; vectors, transformation, host cells Large amounts of the nucleic acids of the present  
15       invention may be produced by replication in a suitable host cell, whether bacterial, yeast, insect, amphibian, avian, mammalian or other eukaryotic cells and expression systems. The natural or synthetic DNA fragments coding for a desired fragment will be incorporated into  
20       recombinant nucleic acid constructs, typically DNA constructs. These DNA constructs are introduced into prokaryotic or eukaryotic cells where they replicate. Usually the DNA constructs are suitable for autonomous replication in a unicellular host, such as yeast or  
25       bacteria. The constructs also can be introduced to and integrated within the genome of a cultured insect, mammalian, plant or other eukaryotic cell lines. Suitable methods for these purposes are well known in the art and have been described, e.g., in Sambrook et al.  
30       (1989) or Ausubel et al. (1987 and periodic updates).

      The nucleic acids of the present invention are optionally produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage and Carruthers (Tetra. Letts. 22:1859-1862, 1981) or the  
35       triesther method according to Matteucci et al. (J. Am.

-37-

Chem. Soc. 103:3185, 1981) and may be performed on commercial automated oligonucleotide synthesizers.

5 DNA constructs prepared for introduction into a prokaryotic or eukaryotic host typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired polypeptide, and preferably also include transcription and translational initiation regulatory sequences operably  
10 linked to the polypeptide encoding segment. Expression vectors include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites,  
15 transcriptional terminator sequences, and mRNA stabilizing sequences. Such vectors are prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) or Ausubel et al. (1987).

20 Appropriate promoter and other necessary vector sequences are selected to function in the host. Examples of functional combinations of cell lines and expression vectors are described in Sambrook et al., 1989 or Ausubel et al., 1987); see also, e.g., Metzger et al., Nature  
25 334:31-36, 1988. Many useful vectors are known in the art and are commercially available. For use in prokaryotic hosts, promoters include but are not limited to the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters. Useful yeast promoters  
30 include but are not limited to the promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Other suitable  
35

-38-

vectors and promoters for use in yeast expression are further described in Hitzeman et al. EP 73,657A.

Appropriate nonnative mammalian promoters include but are not limited to the early and late promoters from SV40 (Fiers et al. Nature 273:113, 1978) or promoters derived from murine molony leukemia virus, mouse mammary tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus and polyoma virus. In addition, the construct can be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene are made.

Such expression vectors can replicate autonomously. In a less preferred mode, the expression vector can replicate by being inserted into the genome of the host cell, by methods well known in the art.

Expression and cloning vectors generally include a selectable marker, which encodes a polypeptide necessary for the survival or growth of its host cells. This gene's presence ensures the growth of only host cells expressing the marker. Typical selection genes encode polypeptides that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media. The choice of the proper selectable marker depends on the host cell. Appropriate markers for different hosts are well known in the art.

Vectors with the nucleic acids of interest can be transcribed *in vitro*, and the resulting RNA are introduced into host cells by well known methods (e.g., by injection). See, T. Kubo et al., FEBS Lett. 241:119, 1988. Alternately, the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host. These methods include but are not limited to

-39-

electroporation; transfection employing calcium chloride, rubidium chloride calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is an infectious agent, such as a retroviral genome). See generally, Sambrook et al. (1989) and Ausubel et al. (1987). The so-transformed cells are also meant to include the progeny of such cells.

Large quantities of the nucleic acids and polypeptides of the present invention are prepared by expressing the nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of *E. coli*, although other prokaryotes, such as *Bacillus subtilis* or *Pseudomonas*, may also be used. Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, amphibian or avian species, may also be useful for production of the polypeptides of the present invention.

The invention has been disclosed by direct description. The following are examples showing the efficacy of the method in producing soluble, active polypeptides. The examples are only examples and should not be taken in any way as limiting to the scope of the invention.

#### EXAMPLES

##### Example 1: Expression and purification of fusion proteins

The following materials and methods used throughout the Examples unless otherwise indicated. Further details can be found in the references cited herein.

-40-

Bacterial strains and growth conditions. *E. coli* JM109 F- traD36 lacIq del(lacZ)M15 proAB / recA1 endA1 gyrA96 thi hsdR17 supE44 relA1 del(lac-proAB).

5 *E. coli* W3110 DE3 F- thi (lambda DE3 lysogen; Studier and Moffat, J. Mol. Biol. 189:113-130, 1986).

These strains were grown in L-Broth at 37°C with aeration unless otherwise indicated. For plasmid-containing strains, antibiotics were added to the growth medium as appropriate.

10 Plasmids. The expression vectors used in this work are essentially identical to pJU1003 (Squires et al., J. Biol. Chem. 263:16297-16302, 1988), except that sequences were inserted downstream of the translational coupler and initiation codon which code for various configurations of the following genes: mature human IGF-1 (70 aa), IGFBP-3 (264 aa), TGF- $\beta$ 2 (112 aa), TGF- $\beta$ -receptor (extracellular domain, 136 aa), or mouse EGF-binding kallikrein (237 aa). In each case a termination codon follows these sequences. These plasmids also differ from pJU1003 in that (a) they do not contain the synthetic 16 bp adaptor sequence at the 5' end of the tet gene in pJU1003; and (b) they contain a DNA insertion at the unique PvuII site in the pBR322-derived backbone consisting of a 385 bp fragment containing the par locus of pSC101 (Meacock and Cohen, Cell 20:529-542, 1980). The plasmids also contain a gene encoding a leaderless *E. coli* periplasmic rotamase downstream of the foreign gene and within the same transcriptional unit. The signal sequence of the rotamase gene was deleted as described by Liu and Walsh, Proc. Natl. Acad. Sci. USA. 87:4028-4032, 1990, and replaced with an initiator methionine codon. The presence of a truncated rotamase gene neutralizes the growth inhibitory effect of ubiquitin fusions in *E. coli* host cells, as disclosed in co-pending application filed

-41-

on even date and entitled "Methods and DNA Expression Systems for Over-Expression of Proteins in Host Cells" with attorney's Docket No. designated 22095-20266.00.

5           Each gene was prepared for expression in four separate configurations to yield the plasmids listed in Table 1: (1) with the 76 codons of yeast ubiquitin ("Ubi") inserted in-frame with and upstream of the gene  
10           sequence; (2) with the 153 codons for mature human IL-1- $\beta$  ("IL1 $\beta$ ") fused in-frame between the initiation codon and the gene, and with a linker encoding Asp-Arg-Gly-Gly inserted between the IL-1- $\beta$  sequence and the gene  
15           sequence; (3) with the 76 codons of yeast ubiquitin inserted between the linker and the gene sequence of configuration (2); and (4) with the 189 codons of mature *E. coli* DsbA followed by a linker encoding His-His-His-His-His-His-Ser, replacing the IL-1- $\beta$  plus linker  
20           sequences of configuration (3). In addition, vectors 12886 and 12887 in which the gene is deleted and replaced with a linker (5'...GGATCCCGTGGAGGATTAAACCATGGATGCATAAGC-TTCGAATTCTGCCAGGCATGCAAGCTCAGATCC...3') are used as controls.

          Six plasmids - pYZ22070, pYZ22096, pYZ9205, pYZ9206, pDM15426, and pDM15424 - contain the T7  
25           transcriptional unit of the above plasmids in a pACYC184 backbone (Chang and Cohen, J. Bacteriol. 134:1141-1156, 1978). Specifically, in these six plasmids, the ClaI-ScaI fragment carrying the T7 promoter, the translational coupler, the gene construct, the rotamase  
30           gene and the T7 terminator replaced the 1.0 kb ClaI-NruI fragment of pACYC184. The pYZ9205 plasmid contains the complete coding sequence for DsbA in the above vector backbone. The pYZ9206 plasmid is identical to pYZ9205 except that the signal sequence of DsbA has been replaced  
35           by a methionine codon. The pDM15426 plasmid is identical

-42-

to pYZ22070 (above) except that it includes the signal sequence of DsbA. The pDM15424 plasmid contains the coding sequence for IL-1-receptor antagonist without its natural signal sequence.

TABLE 1

Config.	Gene				
	IGF-I	IGFBP-3	TGF- $\beta$ 2	TGFR	EGFBP
#1	pDJ16927	pDJ12875	pDJ16920	pDJ16921	pDJ9667
#2	pDM16963	pDM16964	pDM16973	pDM16962	pDM16972
#3	pDM16965	pDM16967	pDM16977		pDM16976
#4	pYZ22070	pDM15427	pYZ22096	pDM15428	pDM15429

Yeast ubiquitin and rotamase sequences were obtained using PCR-mediated amplification from the appropriate genomic DNAs. cDNA clones for IGFBP-3 were isolated as described in Spratt et al., Growth Factors 3:63-72, 1990, and further modified by substituting the amino-terminal one-third of the gene with a synthetic DNA sequence encoding the same amino acids as the natural gene (namely, the initial 288 nucleotides of the mature sequence, up to the unique BssHII site), but using codons optimized for expression in *E. coli* (see, for example, Fiers, Nature 260:500, 1976). The IGF-I sequence was constructed de novo from synthetic DNA and likewise used codons optimized for *E. coli*.

The TGF- $\beta$ 2 sequence was obtained by PCR-mediated modification of a cDNA clone obtained from Dr. Michael Sporn, National Institutes of Health. The TGF- $\beta$ -receptor sequence was similarly derived from pH2-3FF, a cDNA clone from Dr. Herb Lin, Massachusetts Institute of Technology, and the mouse EGF-binding kallikrein sequence from pMS2-12A, a cDNA clone from Dr. Ralph Bradshaw, University of California at

-43-

Riverside. All PCR-derived DNAs were sequenced prior to use.

Each plasmid was introduced into W3110DE3 by calcium chloride-mediated transformation and selection for antibiotic resistance.

Enzymes and reagents. Enzymes and reagents were purchased from New England Biolabs, Beverly, MA; Boehringer Mannheim, Indianapolis, IN; Sigma Chemical Co., St. Louis, MO; Pharmacia, Piscataway, NJ; BRL, Gaithersburg, MD; US Biochemical, Cleveland, OH; and Clontech, Palo Alto, CA.

General techniques. Restriction digests, agarose gel electrophoresis, ligations, transformations, DNA preparation, DNA sequencing, cell culture, SDS-PAGE, Western Blots, ELISA, and other common molecular biological techniques are described in Maniatis et al., Molecular Cloning: A Laboratory Manual, 2d ed., Vols. 1-3, ed. by Sambrook et al., Cold Spring Harbor Laboratory Press, 1989 and Current Protocols in Molecular Biology, ed. F. Ausubel et al., Greene Publishing and Wiley-Interscience: New York, 1987 and periodic updates.

Cell growth and harvest. *E. coli* strain W3110 DE3 containing one of the above plasmids was introduced into 5 ml Luria Broth (LB) containing tetracycline (15 µg/ml) or chloramphenicol (20 µg/ml) and grown to saturation overnight with aeration at 37°C. Two ml of fresh overnight culture was diluted into 100 ml of LB supplemented with 0.2% glucose. The culture was grown with aeration for several hours at the same temperature. The optical density of the culture was followed through early logarithmic growth until the optical density (600 nm) reached 0.4. Then a one ml aliquot was removed and the cells were harvested ("0 minutes" time point).

Isopropyl-thiogalactopyranoside (IPTG) was



-44-

added to a final concentration of 0.4 mM and incubation of the culture continued for two hours. A second aliquot of cells was removed ("120 minutes" time point).

5 Aliquots from these time points were used to prepare "Whole Cell Lysates" (WCL) as described below. The remainder of the culture was harvested by centrifugation, then treated by (1) the "TEX buffer extraction" protocol or (2) a variant of the TEX protocol without the TEX step, the "simple sonication protocol."

10 TEX buffer extraction protocol. Cells were resuspended in 1/10th of the original culture volume of TEX buffer (50 mM Tris-Cl, pH 8.0, 2 mM EDTA, 0.1% Triton X-100) and placed on ice for 20-60 minutes. After  
15 centrifugation in a Beckman TJ-6 centrifuge at 3,000 rpm for 15 minutes at 4°C, the supernatant ("TEX extract" or "T" in the Figures) was removed, and the cell pellet was resuspended in the same volume of TE (10 mM Tris-Cl, pH 8.0, 1 mM EDTA). Cells were disrupted by sonication  
20 using a Branson sonifier (2 x 30 sec bursts). In some experiments, lysis was enhanced by adding 0.2 mg/ml chicken lysozyme to the disruption buffer, although this step did not appear to be necessary. The disrupted cells were centrifuged in a Beckman TJ-6 centrifuge at 3,000  
25 rpm for 15 min at 4°C. The supernatant ("cytoplasmic fraction", or "C" in the Figures) was removed. The pellet was washed once in TE and further resuspended in an equal volume of TE buffer ("insoluble fraction", or "I" in the Figures) for analysis.

30 Simple sonication protocol. Cells were resuspended in 1/10th of the original culture volume of TE (10 mM Tris-Cl, pH 8.0, 1 mM EDTA), and sonicated. All subsequent steps were the same as for the TEX buffer extraction protocol after sonication. However, the  
35 supernatant obtained after sonication in this protocol is

-45-

referred to as the "soluble" fraction (labelled "S" in the Figures) (and represents the sum of the "TEX" and "cytoplasmic" fractions).

5 Whole cell extracts were prepared for electrophoresis by resuspending each whole cell aliquot removed from the culture during growth in 100  $\mu$ l SDS-PAGE sample buffer and boiling for 5 minutes. "Soluble" and "insoluble" fraction samples were prepared by adding one  
10 volume of 2x sample buffer (1% SDS, 10% glycerol, 0.1% bromphenol blue) and incubating at 65°C for 15 minutes.

#### Example 2: Homology between IL-1-like proteins

Figure 1 shows an alignment of the sequences of  
15 five members of the IL-1-like protein family: (1) *E. coli* DsbA, (2) human IL-1- $\beta$ , (3) human IL-1- $\alpha$ , and (4) human basic and (5) human acidic fibroblast growth factors (FGFs). To maximize the alignment, the appropriate regions of the longer members were excluded  
20 from the comparison, notably the oxidoreductase active site loop of DsbA (residues 21-35), and another large loop elsewhere in DsbA (residues 126-157).

When optimally aligned in this fashion, the various members of this group and the toxin coregulated pilus (TcpG) polypeptide, a bacterial homolog of *E. coli*  
25 DsbA from *Vibrio cholerae* (Peek and Taylor, *op. cit.*), exhibit the homologies to IL-1- $\beta$  shown in Figure 2. In addition to the noted homologies, several conservative substitutions may be observed at various positions in the sequences shown in Figure 1, for example, Ile-->Val, Phe-->Tyr, and Asp-->Glu at several positions.  
30

#### Example 3: Accumulation and preferential release of IL-1-like polypeptides and fusions thereof from bacterial cells

35

-46-

Three representative members of the IL-1-like protein family were chosen to exemplify the widespread applicability of polypeptide fusions to IL-1-like polypeptides in order to achieve the accumulation and preferential release of the fusion proteins from bacterial cells: (1) human IL-1- $\beta$ , (2) human IL-1-receptor antagonist (IL-1ra), and (3) *E. coli* DsbA. Mature sequences of IL-1ra and *E. coli* DsbA were expressed, i.e., their naturally encoded amino-terminal signal sequences were replaced with a single initiator methionine codon (pDM15424 and pYZ9206; p15433 is identical to pYZ9206, except that codons V22 to Q35 of DsbA were replaced with codons V22 to P77 of gene III from bacteriophage m13; the expected size of the mutant gene product is approximately 27 kD). For IL-1- $\beta$ , the 153 codons specifying the mature protein were placed downstream of an initiator methionine codon (pDJ12151).

Figure 3 shows the results of the fractionation by SDS-PAGE of *E. coli* cells in which IL-1- $\beta$  is expressed and grown at 37°C. Figure 3A shows whole cell lysates ("WCL") from cells at the 0 minute timepoint; Figure 3B, WCL, 120 minutes; Figure 3C, TEX extract; Figure 3D, "cytoplasmic" fraction; and Figure 3E, "insoluble" fraction. For each gel, lane 1 is wild-type IL-1 $\beta$ , lane 2 is IL-1 $\beta$  triple mutant R4A, L6A, R11G), and lane 3 is IL-1 $\beta$  triple mutant R4D L6A R11G. These two triple mutants are modified at residues which abolish the biological activity of IL-1- $\beta$  without affecting IL-1- $\beta$  binding to at least one of its natural receptors (Gehrke et al., J. Biol. Chem. 265:5922-5925, 1990; Labriola-Tomkins et al, Proc. Natl. Acad. Sci. USA. 88:11182-11186, 1991). The expected size of wild-type or mutant IL-1 $\beta$  in each case is approximately 17 kD (indicated with a • to the right of each gel).

-47-

These gels indicate that the majority of the expressed wild-type IL-1- $\beta$  (lane 1 of Figures 3A-E) was found in the TEX fraction, demonstrating that IL-1- $\beta$  was sequestered to a non-cytoplasmic location *in vivo*. This was not the case with the two triple mutants (R4A L6A R11G, lane 2; and R4D L6A R11G, lane 3). The majority of the expressed IL-1- $\beta$  from these mutants was found in the "insoluble" fraction. These data indicate that even subtle modifications affect the ability of IL-1- $\beta$  to accumulate in a non-cytoplasmic, soluble form.

The data in Table 2 (below) confirm these results, showing that an IL-1- $\beta$ -IGF fusion, like IL-1- $\beta$  itself, is found almost exclusively in the TEX fraction, along with beta-lactamase, a periplasmic protein. Only a small percentage of the IL-1- $\beta$ -IGF fusion protein co-localizes with beta-galactosidase, a cytoplasmic marker.

Figure 4 shows the accumulation and SDS-PAGE fractionation of *E. coli* DsbA. Figure 4a shows whole cell lysates ("WCL") at 0, 60, and 120 minute timepoints from cells expressing mature DsbA (i.e., lacking a leader sequence); Figure 4b, WCL at 0, 60, and 120 minute timepoints from cells expressing a "mutant" mature DsbA with a replacement of the active site loop by approximately 55 amino acids from gene III of bacteriophage m13 (codons V22 to Q35 of DsbA were replaced with codons V22 to P77 of m13 gene III); Figure 4c, TEX extract ("T") and "cytoplasmic" ("C") fractions from cells expressing wild-type mature DsbA; and Figure 4d, "T" and "C" fractions from cells expressing "mutant" DsbA. The expected size of the expressed polypeptide is approximately 22 kD.

Again, virtually all the expressed DsbA protein was found in the TEX fraction. The ability to transfer to an extractable compartment was not lost when the

-48-

"active" site loop of DsbA was replaced by sequences from an unrelated gene.

Figure 5 shows the fractionation of cells in which various fusions of IL-1-like proteins with human IGF-I or TGF- $\beta$  receptor were expressed: (1) IL1 $\beta$ -IGF (pDM16963), with an expected size of approximately 24-25 kD; (2) IL1 $\beta$ -Ubi-IGF (pDM16965), with an expected size of approximately 32 kD; (3) DsbA-Ubi-IGF (pYZ22070), with an expected size of approximately 37 kD; and (4) DsbA-Ubi-TGFR (pDM15428), with an expected size of approximately 46 kD.

The four SDS-PAGE gels in Figure 5, left, show WCL at 0 and 120 minute timepoints of *E. coli* cells expressing these four fusion polypeptides. The four SDS-PAGE gels in Figure 5, right, show TEX and "cytoplasmic" fractions for these four fusion polypeptides. Dots are used to denote the band of the fusion polypeptide and when there is a second dot present, the presence of a breakdown product of the fusion polypeptide.

In all four cases substantial proportions of the fusion proteins were found in the TEX fraction. Thus, these fusions of IL-1-like proteins from cells also substantially transferred to the extractable compartment.

Figure 6 shows whole cell lysates ("WCL") at 0 and 120 minute timepoints and TEX ("T") and "cytoplasmic" ("C") fractions ("FXN") of human IL-1-receptor antagonist expressed in *E. coli* with its natural leader sequence deleted (pDM15424). Again, most of the protein was found in the TEX fraction. This result indicates that IL-1-ra lacking a leader sequence is properly secreted.

Table 2 (below) shows that the TEX fractions of *E. coli* cells expressing IL-1- $\beta$  or an IL-1- $\beta$ -IGF fusion contained a periplasmic enzyme marker,  $\beta$ -lactamase, but not a cytoplasmic marker,  $\beta$ -galactosidase. In the same

-49-

samples, IL-1 immunoreactivity (signifying the presence of the fusion protein) was found almost exclusively in the TEX fraction.

5

-----  
**TABLE 2: Percent of Total Cell Activity**

	<u>Assay</u>	<u>pDJ12151</u> (IL-1- $\beta$ )		<u>pDM16963</u> (IL-1- $\beta$ -IGF)	
		<u>TEX</u>	<u>CYT</u>	<u>TEX</u>	<u>CYT</u>
10	Beta-lactamase	96.4	3.6	96.1	3.9
	Beta-galactosidase	2.3	97.7	6.5	93.5
	Interleukin-1- $\beta$	94.1	5.9	93.2	6.8

-----

15

To confirm a similar localization with mature DsbA, oxidoreductase assays were performed on crude extracts as described by Holmgren (J. Biol. Chem. 254:9627-9632, 1979), except for the following modifications: Assays were performed at room temperature; DTT was at 0.1 mM; and insulin substrate was at 1 mg/ml. The results are provided in Table 3. Like IL-1-ra, DsbA lacking a leader sequence is secreted, resulting in its localization in the TEX fraction.

20

25

30

35

-50-

Table 3: Oxidoreductase Activity of DsbA

	<u>Leader Sequence</u>	<u>Fraction</u>	<u>Activity</u> <u>(U/min-mg)</u>	<u>Percent Total</u> <u>Cell Activity</u>
5	+	T	0.089	87.3
	+	C	0.013	12.7
	-	T	0.100	89.3
	-	C	0.012	10.7

10 T = TEX fraction; C = cytoplasmic fraction

Example 4: Accumulation of soluble fusion polypeptides in bacteria

IL-1-like fusion partners conferred a  
15 pronounced and salutary effect on the solubility of a  
variety of structurally unrelated heterologous proteins  
expressed in bacteria.

Figures 7 through 10 summarize the results  
obtained when the "soluble" (S) and "insoluble" (I)  
20 fractions of induced cells carrying constructs for each  
of four different human genes were compared.

In Figure 7, TGF- $\beta$ 2 fusion constructs were  
analyzed. Figure 7, left, shows Coomassie-stained SDS-  
polyacrylamide gels of whole cell lysates ("WCL") from 0  
25 and 120 minute timepoints and soluble ("S") and insoluble  
("I") fractions from *E. coli* cells which are transformed  
with pDJ16920, which encodes a ubiquitin-TGF- $\beta$ 2 fusion  
polypeptide with an expected size of approximately 20 kD.  
Virtually all of this fusion polypeptide was found in the  
30 "insoluble" fraction. However, with plasmid pYZ22096  
encoding a DsbA-ubiquitin-TGF- $\beta$ 2 fusion of approximately  
42 kD, Figure 7, right, shows the protein was almost  
entirely soluble. These results are also significant in  
that they show that soluble TGF- $\beta$ 2 may be obtained at  
35 37°C. Previous attempts to obtain soluble TGF- $\beta$ 2 relied

-51-

on low temperature growth (e.g., at 30°C), which is less desirable since lower temperature growth is suboptimal for growth of *E. coli* host cells and requires expensive reactor cooling.

In Figure 8 the results obtained with several IGF-I fusions are displayed. Figure 8, left, shows Coomassie-stained SDS-polyacrylamide gels of whole cell lysates ("WCL") from 0 and 120 minute timepoints and soluble ("S") and insoluble ("I") fractions from *E. coli* cells transformed with pDJ16927 and pDM16965. pDJ16927 expresses a ubiquitin-IGF fusion with an expected size of approximately 15 kD. pDM16965 expresses IL1 $\beta$ -ubiquitin-IGF with an expected size of approximately 32 kD.

Figure 8, right, shows similar gels of extracts of *E. coli* cells transformed with pYZ22070, which expresses mature DsbA-ubiquitin-IGF (i.e., DsbA lacking a signal sequence) with an expected size of approximately 37 kD, or with pDM15426, which expresses DsbA-Ubi-IGF in which DsbA retains its native signal sequence and has an expected size of approximately 37 kD.

Figure 9 shows the results obtained with fusions to IGFBP-3. Panel [i] shows the ubiquitin-IGFBP-3 fusion, with an expected size of approximately 38 kD (pDJ12875); panel [ii], IL1-ubiquitin-IGFBP3, with an expected size of approximately 55 kD (pDM16967); and [iii], DsbA-ubiquitin-IGFBP-3, with an expected size of approximately 60 kD (pDM15427). Solubility was markedly higher for the fusion to IL-1.

Figure 10, panel [i], shows whole cell lysates from 0 and 120 minute timepoints and "soluble" ("S") and "insoluble" ("I") fractions from *E. coli* cells expressing a ubiquitin-TGF- $\beta$ R fusion with an expected size of approximately 24 kD (pDJ16921), panel [ii], a DsbA-ubiquitin-TGF- $\beta$ R fusion with an expected size of



-52-

approximately 46 kD (pDM15428;  $\beta$ R is the extracellular domain of the TGF- $\beta$  receptor). The ubiquitin-TGF- $\beta$ R fusion was largely insoluble. In marked contrast, the DsbA-ubiquitin-TGF- $\beta$ R fusion was virtually completely soluble.

Example 5: Biological activity of human IGF-I obtained from fusion proteins in bacterial cells grown at 37° C

Figure 11 shows the effects of temperature and of fusion to DsbA polypeptide on the *in vivo* folding of IGF-I into a biologically active conformation.

The fusion proteins were purified from extracts of these cultures by passing "soluble" fractions prepared from 100 ml of induced cells as described above ("simple sonication protocol") over a Q-Sepharose (Pharmacia) column (5 ml bed volume) equilibrated in 50 mM Tris-Cl, pH 8.0, 1 mM EDTA. The column was washed in two column volumes of the same buffer, and the sample was eluted in 8 ml of the same buffer with an additional 0.4 M NaCl. The eluate was concentrated on a Centricon-30 membrane (Amicon) to a volume of 0.5 ml.

Ubiquitin hydrolase cleavage. To the above concentrate was added 10 $\mu$ l of crude extract of ubiquitin hydrolase enzyme, which was prepared from a strain containing plasmid 23344 as described below in Example 6.

HPLC-reverse phase chromatography. HPLC-reverse phase chromatography was performed as follows. After incubation with ubiquitin hydrolase for 60 minutes at 37°C, the digest was directly applied to a C-18 (Vydac) reverse phase column and subjected to HPLC chromatography in a two-buffer system: Buffer A was aqueous 0.1% trifluoroacetic acid (TFA) and Buffer B was 0.1% TFA in acetonitrile. The column was developed as follows: 0-22% B in 4 minutes; wash in 22% B for 6

-53-

minutes; elute in a 22-42% B gradient at 0.5% per minute (40 minutes total). The IGF-I standard elutes at 31.4% B under these conditions. Peaks were collected, then  
5 diluted for the IGF bioassay (below), or subjected to PAGE analysis. The peak collected from the 31.4% position in all samples contained a single protein band migrating at 7.5 kD as determined by PAGE, with the protein band visualized by silver staining. No  
10 contaminating proteins were observed in this fraction. Peak heights were therefore used to estimate the amount of IGF present by comparison with a commercial IGF standard.

IGF Bioassay. In the IGF bioassay, MG63 cells (ATCC CRL #1427, a male osteosarcoma cell line) were  
15 plated in 96-well microtiter plates at 5000 cells per well and incubated for 16 hours at 37°C in a CO<sub>2</sub> incubator. The culture medium was aspirated and samples (including commercial IGF standards, such as are  
20 available from Imcera, Terre Haute, IN) were added to the wells in RPMI medium, 2mM glutamine, 50 U/ml penicillin, 50 mcg/ml streptomycin, 0.05% bovine serum albumin (BSA).

Serial two-fold dilutions of each sample were tested. Using Cell Proliferation Kit (catalog no. RPN.210, Amersham) cells were incubated for 24 hours at  
25 37°C, the medium was decanted, and 100 µl of the kit's labelling reagent was diluted as directed in the same medium and was added to each well. The plates were then incubated at 37°C for three hours.

30 After the reagent was decanted, the cells were washed in cold PBS three times then fixed by the addition of 100 µl 90% ethanol, 5% acetic acid to each well. The fixed cells were incubated for 30 minutes at room temperature, then washed three times each in (a) PBS +  
35 0.1% Tween-20; (b) PBS + 0.1% Triton X-100, and (c) PBS +

-54-

0.1% Tween-20. Subsequently, the wells were blocked for 15 minutes at room temperature in PBS + 0.1% Tween-20 + 1% nonfat dry milk (NFDM, Carnation brand) and treated with the antibody label provided in the kit according to the manufacturer's protocol (Amersham). The  $A_{405}/A_{490}$  ratio was measured in order to determine 5-bromo-2-dioxyuridine (BRDU) incorporation. The concentration of IGF-I in each sample was determined by comparison with a standard curve. All samples were assayed in triplicate.

Following the binding reaction, samples were chemically cross-linked by addition of 0.3 mM disuccinimidyl suberate at 4°C for 30 minutes. Cross-linking was terminated by adding Tris-HCl, pH 7.5, to a concentration of 20 mM, followed by boiling for 10 minutes. A portion of the cross-linked sample was enzymatically deglycosylated by incubation with N-glycosidase F at 37°C for three hours in the presence of 0.2% 2-mercaptoethanol and 2% SDS. Following this incubation, a second aliquot of N-glycosidase F was added, and the sample was incubated further for one hour. The products of the binding reaction were separated by SDS-PAGE under reducing conditions using a 8% gel. The labeled species were visualized after fixation of the gel in 10% acetic acid, 40% methanol by autoradiography.

Figure 11A and 11B show HPLC-reverse phase elution profiles from ubiquitin hydrolase-cleaved IGF-I derived from cultures of DsbA-ubiquitin-IGF and ubiquitin-IGF constructs, respectively, grown at 30°C. Figures 11C and 11D show the corresponding data from cultures of DsbA-ubiquitin-IGF and ubiquitin-IGF constructs, respectively, grown at 37°C. The position of IGF-I at 31.4% buffer B was established by comparison with a commercial purified IGF standard. It is clear in Figure 11D that at 37°C the ubiquitin fusion did not

-55-

produce properly folded IGF-I (IGF-I is at about 35% B), but the ubiquitin fusion produced properly folded IGF-I at 30°C. Although the temperature dependence of IGF-I folding *per se* was not unexpected, the marked effect of a DsbA fusion partner on the recovery of properly folded IGF-I was surprising (compare Figures 11C and 11D).

The specific activity of the IGF peaks (shown in Figure 11 as boxed values, arbitrary units) was established by the IGF bioassay. In this assay the specific activity of authentic IGF-I was 0.206. In contrast, the specific activity of peak #2, the major peak in Figure 11D (ubiquitin fusion, 37°C), was 0.004.

The amino-terminal protein sequence for the IGF-I peak in Figure 11C was established by Edman degradation in an automated sequencer (Applied BioSystems, Foster City, CA). A single major species was recovered with the sequence Gly-Pro-Glu-Thr-Leu-X-Gly-Ala-Glu-Leu. This was the expected amino terminal sequence for mature IGF-I and shows, additionally, that ubiquitin hydrolase cleaved as precisely as expected.

To exclude the unlikely possibility that the purification of the IGF-I sample prior to HPLC might have influenced the results, crude extracts ("soluble" fraction) from strains carrying the constructs listed in Table 4 were treated with ubiquitin hydrolase, adjusted for total protein concentration and diluted for the IGF bioassay. Cleavage of the fusion protein was confirmed by SDS-PAGE in each case. The crude bioactivities (in arbitrary units) were:

35

-----  
**Table 4: Bioactivity of DsbA Fusion Proteins Cleaved With Ubiquitin Hydrolase**

5	CONSTRUCT	FUSION	BIOACTIVITY
	pDM16927	Ubiquitin-IGF	0.113 $\pm$ 0.009
	pDM15422	(SS-) DsbA-ubiquitin-IGF	0.368 $\pm$ 0.030
	pDM15426	(SS+) DsbA-ubiquitin-IGF	0.242 $\pm$ 0.018

-----

10 These results confirmed the earlier observation that a DsbA fusion partner substantially increases the recovery of biologically active IGF-I from *E. coli*. Bioactive IGF-I was also obtained and analyzed in a similar fashion from fusions containing IL-1- $\beta$  in place of DsbA. The  
 15 IGF-I-DsbA fusions obtained also displayed the correct amino-terminal sequence (GPETLXGA...) after cleavage with ubiquitin hydrolase.

Taken together, these results demonstrate the utility of IL-1-like fusion partners in the production,  
 20 accumulation and recovery of biologically active IGF-I in bacterial cells.

Example 6: Production of yeast ubiquitin hydrolase in bacterial cells and co-expression of fusion polypeptides.

25 Ubiquitin hydrolase (UH) expression vectors were derived from a cDNA clone of UBP-1 (Tobias and Varshavsky, J. Biol. Chem. 266:12021-12028, 1991) by deleting the amino-terminal 92 codons of the gene upstream of the unique BglII site and replacing this DNA  
 30 with (a) the first 12 codons of the phi-10 gene of bacteriophage T7, to yield plasmid 23344; (b) the 153 codons of mature human IL-1- $\beta$ , followed by a linker encoding Asp-Arg-Gly-Asp-Pro-His-His-His-His-His-His-Glu, to produce plasmid 23399; or (c) the 189 codons of *E.*  
 35 *coli* DsbA, followed by a linker encoding His-His-His-His-

-57-

His-His-Ser, followed by the first 75 codons (after methionine) of yeast ubiquitin, followed by a linker encoding Asp-Pro-His-His-His-His-His-His-Glu, to yield plasmid 27246. In each case, the in-frame fusions resulted in a fusion gene under the control of the T7 promoter. The vector backbone and other details of the transcriptional unit used in these experiments are described in Example 1.

Cells of *E. coli* strain W3110 DE3 were transformed with combinations of compatible plasmids as follows:

Table 5: In vivo cleavage of IGF fusions by Ubiquitin Hydrolase (UH)

<u>STRAIN</u>	<u>PLASMIDS</u>	<u>DESCRIPTION</u>	<u>RESULTS</u>
#1	23999 + 15426	Il-1-UH + (SS+)DsbA-ubi-IGF	Minimal cleavage of IGF fusion
#2	27246 + 15426	DsbA-ubi-UH + (SS+)DsbA-ubi-IGF	No cleavage
#3	27246 + 22070	DsbA-ubi-UH + (SS-)DsbA-ubi-IGF	Cleavage virtually complete
#4	23344 + 15422	phi 10-UH + (SS-)DsbA-ubi-IGF	Cleavage virtually complete

After induction with IPTG as described in Example 1, major bands appeared on Coomassie-stained SDS-polyacrylamide gels which corresponded to the expected sizes of IGF fusion protein and the product of its cleavage with UH.

The results shown in Table 5 clearly demonstrate that a protein fusion targeted to the

-58-

periplasmic space via the general secretion pathway is relatively immune to cleavage by UH enzyme fused to either IL-1- $\beta$  or DsbA, but the identical fusion protein sequestered via the alternative pathway used by mature DsbA (i.e., lacking a signal sequence) is effectively cleaved by either cytoplasmic or DsbA-fused UH enzyme. Despite the selective extraction observed for IL-1-like polypeptides and their fusions when expressed in *E. coli* (Example 3), these polypeptides appear to be sequestered in a manner that is different from that of classical periplasmic proteins. These results also show that co-expressed ubiquitin hydrolase genes can efficiently cleave *in vivo* a fusion polypeptide comprising an IL-1-like polypeptide separated from a polypeptide of interest, such as IGF, by a linker containing a ubiquitin hydrolase cleavage site.

Example 7: Purification of TGF receptor fragment and cross-linking assay

The "soluble" fraction prepared from induced cells (100 ml culture volume) containing plasmid pDM15428 was passed over a 1 ml bed volume Ni-NTA affinity column (QIAGEN Inc., Chatsworth, CA), equilibrated, washed and developed according to the manufacturer's recommendations. The eluate was dialysed against the original loading buffer, digested with a partially pure preparation of ubiquitin hydrolase, and passed over an Ni-NTA column identical to that described above. The pass-through was concentrated on a Centricon-10 membrane (Amicon) to a final volume of 0.5 ml. and used for cross-linking assays as follows: 20  $\mu$ l of this sample was incubated overnight with 100 pM  $^{125}$ I-TGF- $\beta$ 1 (250 nM). The sample was cross-linked with 0.3 mM disuccinimidyl suberate (Pierce Chemical, Rockford, IL) for 15 minutes

-59-

at 4°C. The reaction was quenched by the addition of one-third volume of 4x Laemmli gel sample buffer containing 50 mM dithiothreitol. The sample was boiled for two minutes (100°C) and subjected to SDS-PAGE. The gel was dried and visualized by autoradiography with overnight exposure at -80°C.

Figure 12 shows the result of crosslinking experiments using <sup>125</sup>I-radiolabeled TGF-β1 and partially purified TGF-βR (136 amino acid extracellular domain). The expected crosslinked product is observed migrating at about 30 kD. This product is formed by a specific binding interaction, because its appearance is completely abolished by the addition of (1000-fold molar) excess cold TGF-β1. These data show that with the aid of an IL-1-like fusion partner, functional TGF-β receptor can be produced in bacteria.

#### Example 8: IGFBP-3 Dot Blot Assay

For the IGFBP-3 dot blot assay, pre-cut Immobilon-P membrane (Millipore) was soaked in methanol for 5 seconds, rinsed with Tris-buffered saline (TBS), and then soaked in TBS for 10 minutes. The membrane was mounted on a dot blot apparatus and 50 μl TBS was applied to each well. The samples were applied to the membrane by vacuum suction. The membrane was then blocked in TBS + 3% non-fat dry milk (CARNATION brand) at room temperature for two hours. <sup>125</sup>I-radiolabelled IGF-I (1μl per ml blocking buffer) was added, followed by incubation at room temperature for two hours. The buffer was discarded and the filter washed in TBS (2x 15 minute washes at room temperature). The membrane was then air dried for ten minutes then exposed to Kodak XR-Omat film overnight at -80°C.



-60-

Figure 13 shows the results of a dot-blot binding assay using  $^{125}$ I-radiolabeled IGF-I to measure binding activity in crude extracts ("soluble" fraction) of strains expressing (1) a DsbA-ubiquitin-IGFBP-3 fusion (pDM15427), (2) a ubiquitin-IGFBP-3 fusion (pDJ12875), or (3) a "vector only" control (pDJ12887). Similar results were obtained whether the samples were pretreated with ubiquitin hydrolase (+UH) or were not treated (-UH), indicating that the intact fusion proteins can bind the ligand as efficiently as the cleaved IGFBP-3 protein. In this case, no ubiquitin cleavage is necessary to obtain an active protein.

The results clearly show that the DsbA fusion partner increases the recovery of bioactive IGFBP-3 by about 16-fold (4-fold serial dilutions are used on the blot).

Example 9: Expression of IL-1- $\beta$ -IGFBP-3 fusion protein in mammalian cells

Expression plasmid pDM15430, which encodes an IL-1- $\beta$ -IGFBP3 fusion protein in mammalian cells, was constructed by inserting a fusion sequence from plasmid pDM16964 into pDJ12147, a deletion derivative of pRCCMV (InVitrogen Corp, La Jolla, CA) which utilizes a human cytomegalovirus promoter and enhancer and bovine growth hormone polyadenylation signal. The fusion sequence from plasmic pDM16964 comprises codons for an initiator methionine, the 153 amino acids of mature human IL-1- $\beta$  and the 264 amino acids of mature human IGFBP-3.

This construct and the corresponding non-recombinant plasmid ("vector") were used to transiently transfect COS-M6 cells using the DEAE-dextran method (Seed and Aruffo, Proc. Natl. Acad. Sci. USA 84:3365-3369, 1987). Cell extracts were made 72 hours

-61-

after transfection by lysing the cell layer with phosphate buffered saline (PBS) containing 0.2% NP-40 at 4°C for 30 minutes. The extract was centrifuged to remove insoluble debris, and the supernatant was used for binding assays.

Figure 14 shows that endogenous IGF-binding activity was found in COS cell extracts in a broad band in the 45-50 kD size range (Y). Figure 14, right, shows SDS-PAGE of cross-linked samples from COS cells transiently transfected as described above with pDM15430, which encodes IL1 $\beta$ -IGFBP3 ("IL1-BP3"). Figure 14, left, shows SDS-PAGE of cross-linked samples from COS cells transfected with the vector, alone ("vector"). Each set of gels has a left lane with no endoglycosidase F treatment or "cold" IGF competition. The middle lane shows results after treatment with endoglycosidase F, and the right lane shows the results of competition with an excess of "cold" IGF. After treatment of the crosslinked sample with endoglycosidase F as described above, the endogenous IGF binding band was reduced to a sharper band migrating at about 40 kD. In cells transfected with an IL-1- $\beta$ -IGFBP-3 fusion construct, a crosslinked band in the expected size range (approximately 55 kD+, "X" in Figure 14) was observed. However, treatment with endoglycosidase F did not alter the mobility of the X band. This demonstrates that the IL1 $\beta$ -IGFBP-3 fusion protein that accumulated in these cells was not glycosylated. All of the binding observed was specific, as it was successfully competed away with cold IGF (see right lanes of Figure 14).

In parallel experiments, cells transfected with Met-IGFBP-3 constructs lacking the IL-1 fusion partner did not show any detectable IGF binding by the above criteria (data not shown). Other experiments have shown

-62-

that the natural form of the IGFBP-3 gene (i.e., with its own signal sequence) produces a glycosylated product in mammalian cells (Spratt et al., Growth Factors 3:63-72, 1990). Thus, the IL-1 fusion of the present example is likely to be sequestered in the mammalian cell (as is IL-1- $\beta$  itself), but not by virtue of passage through the ER and Golgi, the normal route taken by secreted proteins which would result in glycosylation of the IGFBP-3 protein.

- 63 -

Example 10: Expression of leader-deleted DsbC, mutants and fusions.

A recently identified member of the Dsb family of proteins in *E. coli*, DsbC, bears no obvious primary sequence homology to other previously-described oxidoreductases. This gene had been earlier named *xprA* (Missiakas et al., *EMBO J.* 13:2013-2020, 1994; Lovett and Kolodner, *J. Bacteriol.* 173:353-364, 1991). A leader-deleted version of this gene was cloned into a T7 expression vector which has been described (see, for instance, pYZ22070 in Example 1, above) by PCR using *E. coli* DNA as the template and the primers 5'...GGTGGATCC GATCGTGGAGGATGATTAAATGGCTGATGACGCGCAATTCAACAAAC...3' and 5'...GGGAAGCTTACTCGAGCATGCTACCACCAGATTTACCGCTGGTCA TTTTGG...3'. The resulting plasmid, pDM25492, was further modified as follows: The DNA sequence surrounding the presumed double cysteine active site loop was changed from 5'...ACCTGTGGTTACTGCCACAAA...3' to 5'...ACCGGTAGCGGTTCTGGTAAA ...3' using methods of site-directed mutagenesis well known to those skilled in the art. The resulting plasmid was named pDM46805. Fusions of leader-deleted DsbC (with or without the double cysteine active site loop) to IGF-I were constructed to produce plasmids pDM15486 and pDM46806, respectively.

The DNA sequences of the leader-deleted DsbC variants present in these four plasmids, pDM15486, pDM25492, pDM46805 and pDM46806, are listed in Figures 32, 33, 25, 31, respectively.

Figure 15 shows the proteins expressed by these plasmids when they are introduced into W3110DE3. After induction and selective extraction as described in Example 1 above, samples were separated on 4-20% acrylamide gradient gels, stained with Coomassie Blue and

-64-

photographed. Panels "A" and "B" of Figure 15 show the  
TEX extracts (T) and the remaining soluble fraction (S)  
after sonication of strains carrying pDM25492 and  
5 pDM46805 respectively. The corresponding samples for the  
IGF-I fusion constructs, pDM15486 and pDM46806, are shown  
in panels "C" and "D" of Figure 15. The expected position  
of the DsbC protein is marked by an arrow in each case.

These results clearly indicate that  
10 leader-deleted DsbC is efficiently translocated out of  
the cytoplasm, as are fusions of DsbC to IGF-I. The  
presence of the double cysteine active site loop is  
apparently not required for transport.

15 Example 11: Expression of mini-DsbA and fusions

In order to test the effect of removing the  
entire region surrounding the double cysteine active site  
loop of DsbA, the DsbA expression vector pYZ9206  
(described in Example 1 above) was modified by replacing  
20 the DNA between the unique BssHII and BglII sites of this  
plasmid with synthetic DNA of the sequence:

5'...GCGCGCCTTCTGGTTCTTTCATGGGTGGTGACCTGGGCAAAGATCT...3'

The effect of this replacement (hereinafter referred to  
as "mini-DsbA") is to substitute the amino acids

25 Ser-Gly-Ser for amino acids #21-62 of the original  
(mature) DsbA. The double cysteine active site loop,  
located at #30-33, is deleted by this procedure. The  
resulting plasmid, pDM25452, was further modified by  
fusing ubiquitin and IGF sequences to the  
30 carboxy-terminal end of the mini-DsbA to produce  
pDM25486. pDM25499 is a variant of pDM25486 in which the  
DNA coding for the aminoterminal 45 amino acids of  
ubiquitin have been further deleted.

35

-65-

The DNA sequences of the leader-deleted mini-DsbAs encoded by pDM25452, pDM25486 and pDM25499 are listed in Figures 28, 42 and 41, respectively.

5           Figure 16 shows the proteins expressed by these plasmids when they are tested as described for the constructs in Example 10 above. Panels "A" and "B" show a comparison of pYZ9206 (leader-deleted DsbA) and pDM25452 (leader-deleted mini-DsbA). In each case the induced  
10       samples have been fractionated into TEX (T), remainder soluble (S), and insoluble (I) fractions. Panel "C" shows the results obtained with pDM25499.

          The results show that mini-DsbA is readily translocated out of the cytoplasm and accumulates in  
15       soluble form. The presence of the double cysteine active site loop is apparently irrelevant to the transport function of leader-deleted DsbA.

          Table 6 below describes the plasmids used in the Examples contained herein.

20

25

30

35

-66-

TABLE 6

	<u>Plasmid</u>	<u>Figure</u>	<u>Seq.ID No.</u>	<u>Description</u>
5	25453	20		Native dsbA (with leader) biotinylation peptide
	25450	21		Leaderless dsbA (3' modified)-biotinylation peptide
10	25477	22		Leaderless dsbA (3' modified)-hubi (del145).IGF.new
	41620	23		Leaderless dsbA (3' modified)-hubi .IGF.new
15	9205	24		Native dsbA
	46805	25		Leaderless dsbC (3'modified)C->S variant
20	9206	26		Leaderless dsbA
	22055	27		Leaderless dsbA (3'modified)
	25452	28		Leaderless mini-dsbA (3'modified)
25	22070	29		Leaderless dsbA (3'modified)-y.ubi.IGF.old
	25498*	30		Leaderless dsbC (3'modified)-hubi.IGF.new
30	46806	31		Leaderless dsbC (3'modified)C>S variant IGF1 (new)
	15486	32		Leaderless dsbC (3'modified)-IGF1 (new)
35				

- 67 -

TABLE 6 CONTINUED

	<u>Plasmid</u>	<u>Figure</u>	<u>Seq.ID No.</u>	<u>Description</u>
5	25492	33		Leaderless dsbC (3'modified)
	16963 <sup>b</sup>	34		Mature human interleukin 1 beta (3'modified-IGF (old)
10	12151 <sup>b</sup>	35		Mature human interleukin 1 beta
	15449	36		Mature human interleukin 1 beta (3'modified)
15	25466	37		Human interleukin 1 beta R11G mutant (3'modified)
	99999	38		Interleukin-1 receptor antagonist (3'modified) - IGF1 (new)
20	15424	39		Leaderless interleukin-1 receptor
	16965	40		Mature human interleukin 1 beta (3'modified) - yubi.IGF.old
25	25499	41		Mini-dsbA (3'modified) - hubi(del145).Igf.new
30	25485 <sup>a</sup>	42		Leaderless mini-dsbA (3'modified) - hubi.IGF.new

-----  
<sup>a</sup> in pUC18 vector

<sup>b</sup> in pBR322 vector  
 -----

35



-68-

Example 12: Expression of in vivo -biotinylated DsbA and IL1-beta.

A recent report (Schatz, Bio/Technology 11:1138-1143, 1993) identifies a consensus 13-mer peptide sequence which apparently mimics the target substrate for E. coli biotin holoenzyme synthetase. To investigate the effect of adding this sequence to the carboxy-terminus of DsbA and IL1-beta, the leader-deleted DsbA gene in the vector pYZ22055 (similar to pYZ9206, above, except that the sequence downstream of the carboxy-terminal Lysine codon 189 is synthetic: 5'...CATCATCACCATCATCACAGCATGCCCCG GGCTCGAGTAAGCTTATGCAT...3'; termination codon underlined) was modified by inserting the synthetic sequence:

5'...GCATGGGTTCTCTGAAACCTATCTTTGACGCTCAGAAGATTGAGTGGCGTCA TAGCATGCACCGCGGTCTCGAG...3' between the unique SphI and XhoI sites within the carboxyterminal linker of the dsbA sequence in pYZ22055. This manipulation fuses the biotinylation substrate peptide sequence immediately downstream of the leader-deleted DsbA sequence. The resulting plasmid is pDM25450. The control plasmid pDM25453 is identical to pDM25450 except that the native DsbA leader sequence has been restored in pDM25453.

pDM15457 was constructed in a manner analogous to pDM25450 above. It codes for a biotinylation substrate peptide immediately downstream of IL1-beta. pDM15449 is the parent vector expressing unmodified IL1-beta.

The DNA sequences present in pYZ22055, pDM25450, pDM25453 and pDM15449 are listed in Figures 27, 21, 20 and 35, respectively.

Figure 17 shows the results obtained when the proteins expressed by these plasmids are analyzed as described in the preceding examples (see Examples 1, 10 & 11 above). Only the TEX fractions were subjected to analysis. Gels were stained with Coomassie Blue and

-69-

photographed, or Western-blotted and treated with a reagent kit designed to detect biotinylated protein (Clontech's GENE-TECT Cat.# K1035-1; Palo Alto, CA).

5 Lanes "A", "B", "C" and "D" in each panel were loaded with extracts corresponding to pYZ22055, pDM25450, pDM15449 and pDM15457. The two constructs expressing the 13-mer biotinylation substrate peptide (pDM25450 and pDM15457) provide clear positive signals on the Western blot, whereas the controls do not.

10 To further test this detection system, TEX extracts from pDM25450 and pDM25453 (both coding for the biotinylation substrate 13-mer) were subjected to Ni-NTA affinity chromatography (QUIAGEN, Inc. Chatsworth, CA) according to the manufacturer's instructions. The modified carboxy-terminus of the DsbA protein encoded by these two plasmids contains a run of six histidine residues which facilitate binding to the Ni-NTA resin. After secretion of the pDM25453 protein (when the leader is cleaved off by leader peptidase) the protein should be identical to the leader-deleted version encoded by pDM25450. Thus the only nominal difference between the two DsbA proteins purified in this experiment is the route by which they have been transported out of the cytoplasm: The pDM25453 product by the general secretory pathway, and the pDM25450 product by (presumably) some novel mechanism. When they are tested (panels "E" and "F" respectively) these purified proteins show at least a ten-fold difference in the efficiency with which they have been biotinylated.

30 Separate tests show no difference in the specific enzymatic activity (oxidoreductase) of the two proteins, when assayed as described in Example 3. This suggests that both proteins are folded correctly.

35

-70-

Taken together, these data provide strong evidence for an independent mode of extracytoplasmic transport for leader-deleted DsbA protein.

5

Example 13: Expression and transport of IL1-beta R11G mutant

The effect of substitution mutations at several positions within the interleukin-1-beta sequence has been evaluated with respect to biological activity. The R11G (Arg-11 to Gly) mutant shows normal binding to one IL1 receptor but no biological activity. Receptor-binding suggests normal conformational folding of the protein. Thus, it might be reasonable to suppose that the R11G mutant might be unaffected with respect to its transport function in *E. coli*.

10

pDM25466 is analogous to pDM15449 (see example 12 above) except that codon #11 has been changed from CGG (Arg) to GGG (Gly) by site-directed mutagenesis methods well-known to those skilled in the art. The DNA sequence of the IL1 gene in pDM25466 is listed in Figure 37.

20

Figure 18 shows the fractionation of samples taken from induced cells carrying pDM15449 (panels "A") or pDM25466 (panels "B"). Although the level of accumulation of the mutant protein is reduced, transport clearly occurs.

25

Example 14: Expression of DsbA-yeast MAT alpha-2 homeodomain

30

Approximately 60 amino acids of the yeast alpha-2 homeodomain are sufficient to bind DNA (Wolberger et al., *Cell* 67:517-528, 1991). Using the primers 5'...GGCGGGCATGCACGGTTCAAGTACTAAACCTTACAGAGGA...3' and 5'...GGGGAATTCATGCATTATATTGTTTTTCTTTACGACGACGATTTCGAAACCC AGTTTTTGA...3' and *S. cerevisiae* genomic DNA (Sigma Chem.

35

- 71 -

Co., St. Louis, MO) as a substrate, a 0.22 kb PCR fragment was generated, cleaved with SphI+NsiI and cloned into pYZ22055 vector (above) cut with the same enzymes.

5 The resulting plasmid, pDM15478, carries an in-frame fusion between the carboxy-terminal end of DsbA and the amino-terminal end of the alpha-2 homeodomain. Strains carrying this plasmid were tested as described in the preceding examples.

10 Figure 19A shows the expression of the fusion protein and its partial fractionation into TEX (T) and remainder soluble (S) fractions. Using the Ni-NTA method described in Example 12, purified fusion protein was prepared from (T) and (S) fractions. These purified fractions are shown in panels N1 and N2 of Figure 19A.

15 Figure 19B shows that both purified fractions show DNA-binding activity. The oligonucleotides are exactly as described in Wolberger et al (ibid.) and the control panels are (a) no protein (b) DsbA standard (purchased from Epicentre Technologies, Madison, WI) and  
20 (c) biotinylated DsbA; see example 12, above. (d) and (e) are the purified fusion protein samples N1 and N2. All samples are loaded in duplicate on a TBE acrylamide gradient gel (4-20%). After electrophoresis, the gel is  
25 stained with ethidium bromide (1 microgram per milliliter) and photographed.

The results clearly show DNA binding activity from the fusion protein samples, but not in the controls.

30 All publications and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

35 The invention now being fully described, it will be apparent to one of ordinary skill in the art that

- 72 -

many changes and modifications can be made thereto .  
without departing from the spirit or scope of the  
appended claims..

5

10

15

20

25

30

35

- 73 -

CLAIMS

We claim:

1. A nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising:
  - a) a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like polypeptides and leader-deleted-translocating polypeptides; and
  - b) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner.
2. The nucleic acid of claim 1, wherein the fusion polypeptide further comprises a linker peptide positioned between said fusion partner and said polypeptide of interest.
3. The nucleic acid of claim 2, wherein said linker peptide comprises a polypeptide cleavage site.
4. The nucleic acid of claim 3, wherein said cleavage site is a ubiquitin hydrolase cleavage site.
5. The nucleic acid of claim 1, wherein the mature polypeptide is an interleukin-1-like polypeptide selected from the group consisting of interleukin-1- $\beta$ , interleukin-1 receptor antagonist and *E. coli* DsbA.
6. The nucleic acid of claim 1, wherein the fusion partner is a mutant interleukin-1- $\beta$  fragment defective with respect to interleukin-1- $\beta$  biological activity.

- 74 -

7. The nucleic acid of claim 1, wherein the mature polypeptide is a leader-deleted-translocating polypeptide selected from the group consisting of interleukin-1 receptor antagonist, *E. coli* DsbA, and *E. coli* DsbC.

8. The nucleic acid of claim 1, wherein the fusion partner is a mutant *E. coli* polypeptide variant selected from the group consisting of DsbA and DsbC, wherein said mutant *E. coli* polypeptide fragment lacks a double cysteine active site loop domain.

9. The nucleic acid of claim 1, wherein said polypeptide of interest is a heterologous polypeptide.

10. A nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising:

- a) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature interleukin-1- $\beta$  and a mutant polypeptide variant of mature interleukin-1- $\beta$ , said variant being defective with respect to interleukin-1- $\beta$  biological activity;
- b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and
- c) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest.

11. A nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising:

- a) a fusion partner consisting essentially of a polypeptide selected from the group consisting of

- 75 -

mature *E. coli* DsbA and a mutant polypeptide variant of mature *E. coli* DsbA lacking a double cysteine active site loop domain;

5                   b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and

                  c) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further  
10                   wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest.

12. A nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising:

15                   a) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature *E. coli* DsbC and a mutant polypeptide variant of mature *E. coli* DsbC lacking a double cysteine active site loop domain;

20                   b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and

                  c) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and said linker  
25                   peptide is positioned between said fusion partner and said polypeptide of interest.

13. A nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising:

30                   a) a fusion partner consisting essentially of mature interleukin-1 receptor antagonist;

                  b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and

                  c) a polypeptide of interest, wherein said  
35                   polypeptide of interest is positioned distal to the



-76-

carboxy terminus of said fusion partner, and said linker peptide is positioned between said fusion partner and said polypeptide of interest.

5

14. An expression vector comprising the nucleic acid of claim 1.

10

15. A host cell comprising the nucleic acid of claim 1.

15

16. A host cell comprising:

a) an expression vector capable of expressing in said host cell a fusion polypeptide, said fusion polypeptide comprising,

20

i) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature interleukin-1- $\beta$  and a mutant polypeptide fragment of mature interleukin-1- $\beta$ , said fragment being defective with respect to interleukin-1- $\beta$  biological activity,

ii) a linker peptide comprising a cleavage site, and

25

iii) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest; and

30

b) a nucleic acid capable of expressing in said host cell a proteolytic enzyme which specifically recognizes said cleavage site.

35

-77-

17. A host cell comprising:

a) an expression vector capable of expressing in said host cell a fusion polypeptide, said fusion polypeptide comprising,

i) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature *E. coli* DsbA and a mutant polypeptide variant of mature *E. coli* DsbA lacking a double cysteine active site loop domain,

ii) a linker peptide comprising a cleavage site, and

iii) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest; and

b) a nucleic acid capable of expressing in said host cell a proteolytic enzyme which specifically recognizes said cleavage site.

18. The host cell of claim 16 or 17, wherein said proteolytic enzyme is ubiquitin hydrolase and said cleavage site is a ubiquitin hydrolase site.

19. A fusion polypeptide comprising:

a) a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like polypeptides and leader-deleted-translocating polypeptides; and

b) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner.

-78-

20. The fusion polypeptide of claim 19, further comprising a linker peptide positioned between said fusion partner and said polypeptide of interest.

5

21. The fusion polypeptide of claim 20, wherein said linker peptide comprises a cleavage site.

10

22. The fusion polypeptide of claim 21, wherein said cleavage site is a ubiquitin hydrolase cleavage site.

15

23. The fusion polypeptide of claim 19, wherein the mature polypeptide is an interleukin-1-like polypeptide selected from the group consisting of interleukin-1- $\beta$ , interleukin-1 receptor antagonist and *E. coli* DsbA.

20

24. The fusion polypeptide of claim 19, wherein the mature polypeptide is a leader-deleted-translocating polypeptide selected from the group consisting of interleukin-1 receptor antagonist, *E. coli* DsbA, and *E. coli* DsbC.

25

25. The fusion polypeptide of claim 23 or 24, wherein the fusion partner is the mature polypeptide.

30

26. The fusion polypeptide of claim 19, wherein the fusion partner is a mutant interleukin-1- $\beta$  fragment defective with respect to interleukin-1- $\beta$  biological activity.

35

27. The fusion polypeptide of claim 19, wherein the fusion partner is a mutant *E. coli* polypeptide fragment selected from the group consisting

- 79 -

of DsbA and DsbC, and further wherein said mutant *E. coli* polypeptide fragment lacks a double cysteine active site loop domain.

5

28. The fusion polypeptide of claim 19 wherein said polypeptide of interest comprises a protein selected from the group consisting of an enzyme, a growth factor, an antibody polypeptide, a DNA-binding protein, an RNA binding protein, and a membrane receptor.

10

29. The fusion polypeptide of claim 19 wherein said polypeptide of interest is a heterologous polypeptide.

15

30. A fusion polypeptide comprising:

a) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature interleukin-1- $\beta$  and a mutant polypeptide variant of mature interleukin-1- $\beta$ , said variant being defective with respect to interleukin-1- $\beta$  biological activity;

20

b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and

c) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest.

25

30

31. A fusion polypeptide comprising:

a) a fusion partner consisting essentially of a polypeptide selected from the group consisting of mature *E. coli* DsbA and a mutant polypeptide variant of mature *E. coli* DsbA lacking a double cysteine active site loop domain;

35

-80-

b) a linker peptide comprising a ubiquitin hydrolase cleavage site; and

5 c) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner, and further wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest.

10 32. A method of producing a substantially purified fusion polypeptide encoded by a nucleic acid, wherein said fusion polypeptide comprises,

15 a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like polypeptides and leader-deleted-translocating polypeptides, and

20 a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner;

said method comprising the steps of:

25 a) introducing said nucleic acid encoding said fusion polypeptide into a host cell, thereby producing a transformed host cell;

b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide; and

30 c) purifying said fusion polypeptide, thereby obtaining a substantially purified fusion polypeptide.

35 33. A method of producing a substantially purified polypeptide of interest, said method comprising the steps of:

-81-

a) introducing into a host cell a nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising,

- 5                   i) a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like  
10 polypeptides and leader-deleted-translocating polypeptides, and
- ii) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner,
- 15                   iii) a linker peptide encoding a cleavage site, wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest;

                  thereby producing a transformed host cell;

- 20                   b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide, thereby expressing said fusion polypeptide;

- 25                   c) cleaving said fusion polypeptide with a proteolytic enzyme or cleavage agent which recognizes said proteolytic cleavage site, thereby producing said polypeptide of interest; and

- 30                   d) purifying said polypeptide of interest, thereby obtaining a substantially purified polypeptide of interest.

34. A method of producing a substantially purified polypeptide of interest, said method comprising the steps of:

35

-82-

a) introducing into a host cell a nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising,

- 5                   i) a fusion partner capable of directing extracytoplasmic transport, consisting essentially of at least one fragment of a mature polypeptide, wherein the mature polypeptide is selected from the group consisting of interleukin-1-like  
10 polypeptides and leader-deleted-translocating polypeptides, and
- ii) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner,
- 15                   iii) a linker peptide encoding a cleavage site, wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest;
- thereby producing a transformed host cell;
- 20                   b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide, thereby expressing said fusion polypeptide;
- c) purifying said fusion polypeptide, thereby producing a substantially purified fusion  
25 polypeptide;
- d) cleaving said substantially purified fusion polypeptide with a proteolytic enzyme or cleavage agent which recognizes said proteolytic cleavage site, thereby producing said polypeptide of interest; and  
30                   e) purifying said polypeptide of interest, thereby obtaining a substantially purified polypeptide of interest.
- 35

-83-

35. The method of claim 33 or 34, wherein said fusion partner consists essentially of a polypeptide selected from the group consisting of mature  
5 interleukin-1- $\beta$  and a mutant polypeptide variant of mature interleukin-1- $\beta$ , said variant being defective with respect to interleukin-1- $\beta$  biological activity.

36. The method of claim 33 or 34, wherein said  
10 fusion partner consists essentially of a polypeptide selected from the group consisting of mature *E. coli* DsbA and a mutant polypeptide fragment of said *E. coli* DsbA lacking a double cysteine active site loop domain.

37. The method of claim 33 or 34, wherein said  
15 fusion partner consists essentially of a polypeptide selected from the group consisting of mature *E. coli* DsbC and a mutant polypeptide variant of said *E. coli* DsbC lacking a double cysteine active site loop domain.

20 38. The method of claim 33 or 34, wherein said fusion partner consists of the entire mature interleukin-1 receptor antagonist polypeptide.

25 39. The method of claim 33, wherein said proteolytic enzyme is ubiquitin hydrolase and said cleavage site is a ubiquitin hydrolase site.

30 40. A method of producing a substantially purified polypeptide of interest comprising the steps of:  
a) introducing into a host cell a nucleic acid encoding a fusion polypeptide, said fusion polypeptide comprising,  
i) a fusion partner capable of  
35 directing extracytoplasmic transport, consisting



- 84 -

essentially of at least one fragment of a mature polypeptide, wherein said mature polypeptide is selected from the group consisting of interleukin-1-like polypeptides and leader-deleted-translocating polypeptides, and

ii) a polypeptide of interest, wherein said polypeptide of interest is positioned distal to the carboxy terminus of said fusion partner,

iii) a linker peptide encoding a cleavage site, wherein said linker peptide is positioned between said fusion partner and said polypeptide of interest;

and further wherein said host cell comprises a nucleic acid capable of expressing in said host cell a proteolytic enzyme which specifically recognizes said cleavage site; thereby producing a transformed host cell;

b) culturing said transformed host cell under conditions appropriate for expressing said fusion polypeptide and said proteolytic enzyme, thereby expressing said fusion polypeptide, causing the *in vivo* cleavage of said fusion polypeptide, and producing said polypeptide of interest; and

c) purifying said polypeptide of interest, thereby obtaining a substantially purified polypeptide of interest.

41. The method of claim 40, wherein said fusion partner consists essentially of a polypeptide selected from the group consisting of mature interleukin-1- $\beta$  and a mutant polypeptide variant of mature interleukin-1- $\beta$  said fragment being defective with respect to interleukin-1- $\beta$  biological activity.

-85-

42. The method of claim 40, wherein said  
fusion partner consists essentially of a polypeptide  
selected from the group consisting of mature *E. coli* DsbA  
and a mutant polypeptide variant of mature *E. coli* DsbA  
5 lacking a double cysteine active site loop domain.

43. The method of claim 40, wherein said  
proteolytic enzyme is ubiquitin hydrolase and said  
10 cleavage site is a ubiquitin hydrolase cleavage site.

15

20

25

30

35

1/38

(1)dsbA: (19)AQYEDGK---QYTTLE---KP-VAGAP FEE-VL  
 (2)IL1b: APVR---SLNCTLRDSQQKSLVMSGP YELKAL  
 (3)IL1a: APF-SFLSNVKYNFMRIIKYEFILNDA IRANDQ  
 (4)FGFb: (14)GHFKDPK-RLYC-KNGG--F-FLRIHP -DGRV-  
 (5)FGFa: ( 5)GNYKKPK-LLYCS-NGG--Y-FLRILP -DGTV-

(1) HISDNVKKKLPEGVKMTKYHVNF-MGGDL-GKDLTQAWAVAM-  
 (2) HLQ-----GQDM-EQQVVFMSF-VQGEESNDKIPVAL-  
 (3) YLTAAAL-----HNL-DEAVKFDMGA-YKSSKDDAKITVIL-  
 (4) ---DGVREK-----SDPHIKLQ----LQAEE---RGVVSİK  
 (5) ---DGTKDR-----SDQHIQLQ----LCAESI---GEVYİK


(1) AL-----GVEDKVTVPLFEGV--OQTQTIRSASDIRDVF  
 (2) GLKEKNLYLSCVLKDDKPTLQL-ESVD-PKNYPKKKM-EKRFVF  
 (3) RISK TQLYVTAQD-EDQPVLLK-EMPEIPKTIT--GS-ETNLLF  
 (4) GV-CANRYL--AMKED---GRLLAS-----KCVTDECFFF  
 (5) ST-ETGQFL--AMDTD---GLLYGS-----QTP---NEECFL



(1) INAGI--KGEEYDAA KYQLNPQGMDS---NMDVF-V-----  
 (2) NKIEINNKL-EFESA --QFPNWIISTSAENMPVF-LGGTKGG  
 (3) FWETHGTKN-YFTSV --AHPNLFIA TKQ--DYWVC-L--AGGP  
 (4) ERLESNNYN-TYRSR KY--TSWYVALKRTGQ---YKLGSKTGP  
 (5) ERLEENHYN-TYISK KHAEKHWFVGLKKNGR---SKLGPRTHF

(1) QQYAD-TVKYL--SEKK  
 (2) QDITDFTMQFV----SS  
 (3) PSITDFQILEN----QA  
 (4) GQKA---ILFLPMSAKS  
 (5) GQKA---ILFLPLPVSS

FIG. 1

2/38

**FIG. 2**



4/38




FIG. 5

5/38


Human IL1-receptor antagonist in E.coli

FIG. 6

6/38


(A) IGF-beta 2

FIG. 7

(B) IGF-I

FIG. 8



7/38

(C) IGFBP3




FIG. 9

(D) TGFb-R-ECD





FIG. 10

8/38

**FIG. 11**

SUBSTITUTE SHEET (RULE 26)

9/38





FIG. 12



SUBSTITUTE SHEET (RULE 26)

FIG. 13

10/38




FIG. 14

11/38






FIG. 15

12/38

T S



T S I



T S I



FIG. 16

13/38

Western Blot

Coomassie





FIG. 17

14/38




FIG. 18



15/38




FIG. 19

16/38

A. Native dsbA (with leader)-biotinylation peptide  
Plasmid 25453

ATGAAAAAGA TTTGGCTGGC GCTGGCTGGT TTAGTTTTAG CGTTTAGCGC  
ATCGGCGGCG CA GTATGAAGAT GGTAACAGT AACTACCCT  
GGAAAAACCG GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTCT  
TCTGCCCCGA CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT  
GTGAAGAAAA AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA  
CTTCATGGGT GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG  
CGATGGCGCT GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC  
GTACAGAAAA CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT  
TATCAACGCA GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT  
TCGTGGTGAA ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG  
CAATTGCGTG GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA  
TCCGCAGGGT ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG  
CTGATACAGT GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC  
AGCATGGGTTCTCTGAAACCTATCTTTGACGCTCAGAAGATTGAGTGGCGTCAT  
AGCATGCACCGCGGTCTCGAGTAA

**FIG. 20**

17/38

B. Leaderless dsbA (3' modified)-biotinylation peptide  
Plasmid 25450

ATGGCGCA GTATGAAGAT GGTAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGCA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGCGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC  
AGCATGGGTTCTCTGAAACCTATCTTTGACGCTCAGAAGATTGAGTGGCGTCAT  
AGCATGCACCGCGGTCTCGAGTAA

**FIG. 21**

18/38

C. Leaderless dsbA (3' modified)-hubi(del45).IGF.new  
Plasmid 25477

ATGGCGCA GTATGAAGAT GGTAACAGT AACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCGCA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC  
AGCATGCCCCGCAAGCAGCTAGAAGACGGTAGAACGCTGTCTGATTACAACATTGAG  
AAGGAGTCCACCTTACATCTTGTGCTAAGGCTCCGCGGTGGTGGTCCGGAACCCCTG  
TGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGGTTTCTAC  
TTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACCGGTATC  
GTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGTCTGGAAATGTACTGCGCT  
CCGCTGAAACCGGCTAAATCCGCTTAA

**FIG. 22**

19/38

D. Leaderless dsbA (3' modified)-hubi.IGF.new Plasmid  
41620

ATGGCGCA GTATGAAGAT GGTAACAGT ACACTACCCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC  
AGCATGCAGATTTTCGTCAAGACTTTGACCGGTAAAACCATAACATTGGAAGTTGAA  
CCTTCCGATACCATCGAGAACGTTAAGGCGAAAATCAAGACAAGGAAGGTATCCCT  
CCAGATCAACAAAGATTGATCTTTGCCGGCAAGCAGCTAGAAGACGGTAGAACGCTG  
TCTGATTACAACATTCAGAAGGAGTCCACCTTACATCTTGTGCTAAGGCTCCGCGGT  
GGTGGTCCGGAAACCCTGTGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGC  
GGTGACCGTGTTTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGT  
GCTCCGCAGACCGGTATCGTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGT  
CTGGAAATGTACTGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

**FIG. 23**

20/38

H. Native dsbA  
Plasmid 9205

ATGAAAAAGA TTTGGCTGGC GCTGGCTGGT TTAGTTTTAG CGTTTAGCGC  
ATCGGCGGCG CA GTATGAAGAT GGTAACAGT AACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AATAA

**FIG. 24**

21/38

I. Leaderless dsb\_C (3' end modified) C->S variant  
Plasmid 46805

ATGGCTGATGACGCGGCA ATTCAACAAACGTTA  
GCCAAAATGGGCATCAAAAGCAGC  
GATATTCAGCCCGCGCCTGTAGCTGGCATGAAGACAGTTCTG  
ACTAACAGCGGCGTGTTGTACATC  
ACCGATGATGGTAAACATATCATTGAGGGGCCAATGTATGACGTTAGTGGCACGGCT  
CCG GTCAATGTCACCAATAAGATGCTGTTA  
AAGCAGTTGAATGCGCTTGAAAAAGAG ATGATCGTTTATAAAGCG  
CCGCAGGAAAAACACGTCATCACCGTG  
TTTACTGATATTACCGGTAGCGGTTCTGGTAAACTGCATGAGCAAATGGCAGACTAC  
AACGCGCTGGGG  
ATCACCGTGCGTTATCTTGCTTTCCCGCGCCAGGGGCTGGACAGCGATGCA  
GAGAAAGAAATGAAAGCTATCTGGTGTGCGAAAGATAAAAAACAAAGCGTTTGATGAT  
GTGATGGCAGGTAAAAGCGTCGCACCAGCCAGTTGCGACGTGGATATTGCCGACCAT  
TACGCA CTTGGCGTCCAGCTTGCGGTTAGCGGTACTCCGGCAGTTGTG  
CTGAGCAATGGCACACTTGTTCCGGGTTACCAG  
CCGAAAGAGATGAAAGAATTCCTCGACGAACAC  
CAAAAAATGACCAGCGGTAAATCTGGTGGTAGCATGC

FIG. 25

22/38

J. Leaderless dsbA  
Plasmid 9206

ATGGCGCA GTATGAAGAT GGTAACAGT AACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGCA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AATAA

**FIG. 26**



23/38

K. Leaderless dsbA (3' modified)  
Plasmid 22055

ATGGCGCA GTATGAAGAT GGTAAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTG AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTG CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC AGCATGCCCCG  
GGCTCGAGTA AGCTTATGCA T

FIG. 27

24/38

L. Leaderless mini-dsBA (3' modified)  
Plasmid 25452

ATGGCGCA GTATGAAGAT GGTAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCTTCTGG TTCTTTCATG GGTGGTGACC TGGGCAAAGA  
TCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT GGGCGTGGA  
GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA CCCAGACCAT  
TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA GGTATTAAAG  
GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA ATCTCTGGTC  
GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG GCGTTCCGGC  
GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT ATGGATACCA  
GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT GAAATATCTG  
TCCGAGAAAA AATAA

**FIG. 28**

25/38

M. Leaderless dsbA (3' modified)-y.ubi.IGF.old  
Plasmid.22070

ATGGCGCA GTATGAAGAT GGTAAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCGCAAGT GCTGGAGTTT TTCTCTTTCT TCTGCCCCGA  
CTGCTATCAG TTTGAAGAAG TTCTGCATAT TTCTGATAAT GTGAAGAAAA  
AACTGCCGGA AGGCGTGAAG ATGACTAAAT ACCACGTCAA CTTCATGGGT  
GGTGACCTGG GCAAAGATCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT  
GGGCGTGGAA GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA  
CCCAGACCAT TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA  
GGTATTAAAG GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA  
ATCTCTGGTC GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG  
GCGTTCCGGC GATGTTTGTT AACGGTAAAT ATCAGCTGAA TCCGCAGGGT  
ATGGATACCA GCAATATGGA TGTTTTTGTT CAGCAGTATG CTGATACAGT  
GAAATATCTG TCCGAGAAAA AACATCATCA CCATCATCAC  
AGCATGCAGATTTTCGTCAAGACTTTGACCGGTAAAACCATAACATTGGAAGTTGAA  
TCTTCCGATACCATCGACAACGTTAAGTCGAAAATTCAAGACAAGGAAGGTATCCCT  
CCAGATCAACAAAGATTGATCTTTGCCGGTAAGCAGCTAGAAGACGGTAGAACGCTG  
TCTGATTACAACATTGAGAAGGAGTCCACCTTACATCTTGTGCTAAGGCTCCGCGGT  
GGTGGTCCGGAAACCCTGTGCGGTGCTGAACTGGTTGACGCTCTGCAGTTCGTTTGC  
GGTGACCGTGGTTTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGT  
GCTCCGCAGACCGGTATCGTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGT  
CTGGAAATGTACTGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

FIG. 29

26/38

N. Leaderless dsb\_C (3' end modified) -hubi.IGF.new  
Plasmid 25498 (Vector pUC18)

ATGGCTGATGACGCGGCA ATTCAACAAACGTTA  
GCCAAAATGGGCATCAAAGCAGC  
GATATTCAGCCCGCGCCTGTAGCTGGCATGAAGACAGTTCTG  
ACTAACAGCGGCGTGTTGTACATC  
ACCGATGATGGTAAACATATCATTGAGGGCCAATGTATGACGTTAGTGGCACGGCT  
CCG GTCAATGTCACCAATAAGATGCTGTTA  
AAGCAGTTGAATGCGCTTGAAAAGAG ATGATCGTTTATAAAGCG  
CCGCAGGAAAAACACGTCATCACCGTG  
TTTACTGATATTACCTGTGGTTACTGCCACAACTGCATGAGCAAATGGCAGACTAC  
AACGCGCTGGGG  
ATCACCGTGCGTTATCTTGCTTTCCCGCGCCAGGGGCTGGACAGCGATGCA  
GAGAAAGAAATGAAAGCTATCTGGTGTGCGAAAGATAAAAACAAAGCGTTTGATGAT  
GTGATGGCAGGTAAAAGCGTCGCACCAGCCAGTTGCGACGTGGATATTGCCGACCAT  
TACGCA CTTGGCGTCCAGCTTGCGGTTAGCGGTACTCCGGCAGTTGTG  
CTGAGCAATGGCACACTTGTTCCGGGTTACCAG  
CCGAAAGAGATGAAAGAATTCCTCGACGAACAC  
CAAAAAATGACCAGCGGTAAATCTGGTGGTAGCATGCAGATTTTCGTCAAGA  
CTTTGACCGGTAAAACCATAACATTGGAAGTTGAACCTTCCGATACCATCGAGAACG  
TTAAGGCGAAATTCAGACAAGGAAGGTATCCCTCCAGATCAACAAAGATTGATCT  
TTGCCGCAAGCAGCTAGAAGACGGTAGAACGCTGTCTGATTACAACATTGAGAAGG  
AGTCCACCTTACATCTTGCTAAGGCTCCGCGGTGGTGGTCCGGAAACCTGTGCG  
GTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGGTTTCTACTTCA  
ACAAACCGACCGGTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACCGGTATCGTTG  
ACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGTCTGGAAATGTACTGCGCTCCGC  
TGAAACCGGCTAAATCCGCTTAA

FIG. 30

27/38

O. Leaderless dsb\_C (3' end modified) C->S  
variant-IGF1(new)  
Plasmid 46806

ATGGCTGATGACGCGGCA ATTCAACAAACGTTA  
GCCAAAATGGGCATCAAAAGCAGC  
GATATTCAGCCCGCGCCTGTAGCTGGCATGAAGACAGTTCTG  
ACTAACAGCGGCGTGTTGTACATC  
ACCGATGATGGTAAACATATCATTGAGGGGCCAATGTATGACGTTAGTGGCACGGCT  
CCG GTCAATGTCACCAATAAGATGCTGTTA  
AAGCAGTTGAATGCGCTTGAAAAAGAG ATGATCGTTTATAAAGCG  
CCGCAGGAAAAACACGTCATCACCGTG  
TTTACTGATATTACCGGTAGCGGTTCTGGTAACTGCATGAGCAAATGGCAGACTAC  
AACGCGCTGGGG  
ATCACCGTGCGTTATCTTGCTTTCCCGCGCCAGGGGCTGGACAGCGATGCA  
GAGAAAGAAATGAAAGCTATCTGGTGTGCGAAAGATAAAAACAAAGCGTTTGATGAT  
GTGATGGCAGGTAAAAGCGTCGCACCAGCCAGTTGCGACGTGGATATTGCCGACCAT  
TACGCA CTTGGCGTCCAGCTTGCGGTTAGCGGTACTCCGGCAGTTGTG  
CTGAGCAATGGCACACTTGTTCCGGGTTACCAG  
CCGAAAGAGATGAAAGAATTCCTCGACGAACAC  
CAAAAAATGACCAGCGGTAAATCTGGTGGTAGCATGCACCGCGGTGGTGGTCCGGAA  
ACCCTGTGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGGT  
TTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACC  
GGTATCGTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGTCTGGAAATGTAC  
TGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

FIG. 31

28/38

P. Leaderless dsb\_C (3' end modified) - IGF1(new)  
Plasmid 15486

ATGGCTGATGACGCGGCA ATTCAACAAACGTTA  
GCCAAAATGGGCATCAAAGCAGC  
GATATTCAGCCCGCGCCTGTAGCTGGCATGAAGACAGTTCTG  
ACTAACAGCGGCGTGTGTACATC  
ACCGATGATGGTAAACATATCATTGAGGGGCCAATGTATGACGTTAGTGGCACGGCT  
CCG GTCAATGTCACCAATAAGATGCTGTTA  
AAGCAGTTGAATGCGCTTGAAAAAGAG ATGATCGTTTATAAAGCG  
CCGCAGGAAAAACACGTCATCACCGTG  
TTTACTGATATTACCTGTGGTTACTGCCACAACTGCATGAGCAAATGGCAGACTAC  
AACGCGCTGGGG  
ATCACCGTGCGTTATCTTGCTTTCCCGCGCCAGGGGCTGGACAGCGATGCA  
GAGAAAGAAATGAAAGCTATCTGGTGTGCGAAAGATAAAAACAAAGCGTTTGATGAT  
GTGATGGCAGGTAAAAGCGTCGCACCAGCCAGTTGCGACGTGGATATTGCCGACCAT  
TACGCA CTTGGCGTCCAGCTTGGCGTTAGCGGTACTCCGGCAGTTGTG  
CTGAGCAATGGCACACTTGTTCCGGGTACCAG  
CCGAAAGAGATGAAAGAATTCCTCGACGAACAC  
CAAAAAATGACCAGCGGTAAATCTGGTGGTAGCATGCACCGCGGTGGTGGTCCGGAA  
ACCCTGTGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGGT  
TTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACC  
GGTATCGTTGACGAATGCTGCTTCCGGTCCCTGCGACCTGCGTCGTCTGGAAATGTAC  
TGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

FIG. 32

29/38

Q. Leaderless dsb\_C (3' end modified)  
Plasmid 25492

ATGGCTGATGACGCGGCA ATTCAACAAACGTTA  
GCCAAAATGGGCATCAAAAGCAGC  
GATATTCAGCCCGCGCCTGTAGCTGGCATGAAGACAGTTCTG  
ACTAACAGCGGCGTGTGTACATC  
ACCGATGATGGTAAACATATCATTGAGGGGCAATGTATGACGTTAGTGGCACGGCT  
CCG GTCAATGTCACCAATAAGATGCTGTTA  
AAGCAGTTGAATGCGCTTGAAAAAGAG ATGATCGTTTATAAAGCG  
CCGCAGGAAAAACACGTCATCACCGTG  
TTTACTGATATTACCTGTGGTTACTGCCACAACTGCATGAGCAAATGGCAGACTAC  
AACGCGCTGGGG  
ATCACCGTGCGTTATCTTGCTTTCCCGCGCCAGGGGCTGGACAGCGATGCA  
GAGAAAGAAATGAAAGCTATCTGGTGTGCGAAAGATAAAAACAAAGCGTTTGATGAT  
GTGATGGCAGGTAAAAGCGTCGCACCAGCCAGTTGCGACGTGGATATTGCCGACCAT  
TACGCA CTTGGCGTCCAGCTTGGCGTTAGCGGTACTCCGGCAGTTGTG  
CTGAGCAATGGCACACTTGTTCCGGGTTACCAG  
CCGAAAGAGATGAAAGAATTCCTCGACGAACAC  
CAAAAAATGACCAGCGGTAAATCTGGTGGTAGCATGC

**FIG. 33**

30/38

R. Mature human interleukin 1 beta (3' end  
modified) - IGF (old)  
Plasmid 16963 (vector pBR322)

ATGGCACC TGTACGATCA CTGAACTGCA CGCTCCGGGA CTCACAGCAA  
AAAAGCTTGG TGATGTCTGG TCCATATGAA CTGAAAGCTC TCCACCTCCA  
GGGACAGGAT ATGGAGCAAC AAGTGGTGTG CTCCATGTCC TTTGTACAAG  
GAGAAGAAAG TAATGACAAA ATACCTGTGG CCTTGGGCCT CAAGGAAAAG  
AATCTGTACC TGTCTGCGT GTTGAAAGAT GATAAGCCCA CTCTACAGCT  
GGAGAGTGTA GATCCCAAAA ATTACCCAAAGAAGAAGATGGAAAAGCGAT  
TTGTCTTCAA CAAGATAGAA ATCAATAACA AGCTGGAATT TGAGTCTGCC  
CAGTTCCCCA ACTGGTACAT CAGCACCTCT CAAGCAGAAA ACATGCCCGT  
CTTCCTGGGA GGGACCAAAG GCGGCCAGGA TATAACTGAC TTCACCATGC  
AATTTGTGTC TTCC GACCGCGG  
TGGCATGCACCGCGGTGGTGGTCCGGAAACCCTGTGCGGTGCTGAACTGGTTGACGC  
TCTGCAGTTCGTTTGCAGTGACCGTGGTTTCTACTTCAACAAACCGACCGGTTACGG  
TTCCTCCTCCCGTCGTGCTCCGCAGACCGGTATCGTTGACGAATGCTGCTTCCGGTC  
CTGCGACCTGCGTCGTCTGGAAATGTACTGCGCTCCGCTGAAACCGGCTAAATCCGC  
TTAA

**FIG. 34**



31/38

S. Mature human interleukin 1 beta  
Plasmid 12151 (vector pBR322)

```
ATGGCACC TGTACGATCA CTGAACTGCA      CGCTCCGGGA
CTCACAGCAA AAAAGCTTGG TGATGTCTGG TCCATATGAA CTGAAAGCTC
TCCACCTCCA GGGACAGGAT ATGGAGCAAC AAGTGGTGTT CTCCATGTCC
TTTGTACAAG GAGAAGAAAG TAATGACAAA ATACCTGTGG CCTTGGGCCT
CAAGGAAAAG AATCTGTACC TGTCTGCGT GTTGAAAGAT GATAAGCCCA
CTCTACAGCT GGAGAGTGTA GATCCCAAAA
ATTACCCAAAGAAGAAGATGGAAAAGCGAT TTGTCTTCAA CAAGATAGAA
ATCAATAACA AGCTGGAATT TGAGTCTGCC CAGTTCCCCA ACTGGTACAT
CAGCACCTCT CAAGCAGAAA ACATGCCCGT CTCCTGGGA GGGACCAAAG
GCGGCCAGGA TATAACTGAC TTCACCATGC AATTGTGTC TTCCTAA
```

**FIG. 35**

32/38

T. Mature human interleukin 1 beta (3' end modified)  
Plasmid 15449

ATGGCACC TGTACGATCA CTGAACTGCA CGCTCCGGGA  
CTCACAGCAA AAAAGCTTGG TGATGTCTGG TCCATATGAA CTGAAAGCTC  
TCCACCTCCA GGGACAGGAT ATGGAGCAAC AAGTGGTGTT CTCCATGTCC  
TTTGTACAAG GAGAAGAAAG TAATGACAAA ATACCTGTGG CCTTGGGCCT  
CAAGGAAAAG AATCTGTACC TGTCTGCGT GTTGAAAGAT GATAAGCCCA  
CTCTACAGCT GGAGAGTGTA GATCCCAAAA  
ATTACCCAAAGAAGAAGATGGAAAAGCGAT TTGTCTTCAA CAAGATAGAA  
ATCAATAACA AGCTGGAATT TGAGTCTGCC CAGTTCCCCA ACTGGTACAT  
CAGCACCTCT CAAGCAGAAA ACATGCCCGT CTCCTGGGA GGGACCAAAG  
GCGGCCAGGA TATAACTGAC TTCACCATGC AATTTGTGTC TTCC GACCGCGG  
TGGCATGC

**FIG. 36**

33/38

U. Human interleukin 1 beta R11G mutant (3' end  
modified)  
Plasmid 25466

ATGGCACC TGTACGATCA CTGAACTGCA CGCTCGGGGA  
CTCACAGCAA AAAAGCTTGG TGATGTCTGG TCCATATGAA CTGAAAGCTC  
TCCACCTCCA GGGACAGGAT ATGGAGCAAC AAGTGGTGTT CTCCATGTCC  
TTTGTACAAG GAGAAGAAAG TAATGACAAA ATACCTGTGG CCTTGGGCCT  
CAAGGAAAAG AATCTGTACC TGTCCTGCGT GTTGAAAGAT GATAAGCCCA  
CTCTACAGCT GGAGAGTGTA GATCCCAAAA  
ATTACCCAAAGAAGAAGATGGAAAAGCGAT TTGTCTTCAA CAAGATAGAA  
ATCAATAACA AGCTGGAATT TGAGTCTGCC CAGTTCCCCA ACTGGTACAT  
CAGCACCTCT CAAGCAGAAA ACATGCCCCGTTTCCTGGGA GGGACCAAAG  
GCGGCCAGGA TATAACTGAC TTCACCATGC AATTTGTGTC TTCCAGCATGC

**FIG. 37**

34/38

V. Interleukin-1 receptor antagonist (3'  
modified) - IGF1 (new)

ATGCGGCCGT CTGGGAGAAA ATCCAGCAAG ATGCAAGCCT TCAGAATCTG  
GGATGTTAAC CAGAAGACCT TCTATCTGAG GAACAACCAA CTAGTTGCTG  
GATACTTGCA AGGACCAAAT GTCAATTTAG AAGAAAAGAT AGATGTGGTA  
CCCATTGAGC CTCATGCTCT GTTCTTGGGA ATCCATGGAG GGAAGATGTG  
CCTGTCCTGT GTCAAGTCTG GTGATGAGAC CAGACTCCAG CTGGAGGCAG  
TTAACATCAC TGACCTGAGC GAGAACAGAA AGCAGGACAA GCGCTTCGCC  
TTCATCCGCT CAGACAGTGG CCCCACCACC AGTTTTGAGT CTGCCGCCTGC  
CCCGGTTGGT TCCTCTGCAC AGCGATGGAA GCTGACCAGC CCGTCAGCCT  
CACCAATATG CCTGACGAAG GCGTCATGGT CACCAAATTC  
TACTTCCAGGAGGACGAGTCTGGTTCTGGTGACGATGACGATAAGAGCATGCACCGC  
GGTGGTGGTCCGGAAACCCTGTGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTT  
TGCGGTGACCGTGGTTTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGT  
CGTGCTCCGCAGACCGGTATCGTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGT  
CGTCTGGAAATGTACTGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

**FIG. 38**

35/38

W. Leaderless interleukin-1 receptor antagonist (3'  
modified)  
Plasmid 15424

ATGCGGCCGT CTGGGAGAAA ATCCAGCAAG ATGCAAGCCT TCAGAATCTG  
GGATGTTAAC CAGAAGACCT TCTATCTGAG GAACAACCAA CTAGTTGCTG  
GATACTTGCA AGGACCAAAT GTCAATTTAG AAGAAAAGAT AGATGTGGTA  
CCCATTGAGC CTCATGCTCT GTTCTTGGGA ATCCATGGAG GGAAGATGTG  
CCTGTCCTGT GTCAAGTCTG GTGATGAGAC CAGACTCCAG CTGGAGGCAG  
TTAACATCAC TGACCTGAGC GAGAACAGAA AGCAGGACAA GCGCTTCGCC  
TTCATCCGCT CAGACAGTGG CCCCACCACC AGTTTTGAGT CTGCCGCCTGC  
CCCGGTTGGT TCCTCTGCAC AGCGATGGAA GCTGACCAGC CCGTCAGCCT  
CACCAATATG CCTGACGAAG GCGTCATGGT CACCAAATTC TACTTCCAGG  
AGGACGAGTA AGTACTTGCTA AAATGTACCC TAGGCCTCCC GGGCTCGAGT  
AAGCTTATGC AT

**FIG. 39**

36/38

X. Mature human interleukin 1 beta (3' end  
modified)-yubi.IGF.old  
Plasmid 16965

ATGGCACC TGTACGATCA CTGAACTGCA CGCTCCGGGA  
CTCACAGCAA AAAAGCTTGG TGATGTCTGG TCCATATGAA CTGAAAGCTC  
TCCACCTCCA GGGACAGGAT ATGGAGCAAC AAGTGGTGTT CTCCATGTCC  
TTTGTACAAG GAGAAGAAAG TAATGACAAA ATACCTGTGG CCTTGGGCCT  
CAAGGAAAAG AATCTGTACC TGTCCTGCGT GTTGAAAGAT GATAAGCCCA  
CTCTACAGCT GGAGAGTGTA GATCCCAAAA  
ATTACCCAAAGAAGAAGATGGAAAAGCGAT TTGTCTTCAA CAAGATAGAA  
ATCAATAACA AGCTGGAATT TGAGTCTGCC CAGTTCCCCA ACTGGTACAT  
CAGCACCTCT CAAGCAGAAA ACATGCCCGT CTCCTGGGA GGGACCAAAG  
GCGGCCAGGA TATAACTGAC TTCACCATGC AATTTGTGTC TTCC GACCGCGG  
TGGCATGCAGATTTTCGTCAAGACTTTGACCGGTAAAACCATAACATTGGAAGTTGA  
ATCTTCCGATACCATCGACAACGTTAAGTCGAAAATTCAAGACAAGGAAGGTATCCC  
TCCAGATCAACAAAGATTGATCTTTGCCGGTAAGCAGCTAGAAGACGGTAGAACGCT  
GTCTGATTACAACATTCAGAAGGAGTCCACCTTACATCTTGTGCTAAGGCTCCGCGG  
TGGTGGTCCGGAAACCCTGTGCGGTGCTGAACTGGTTGACGCTCTGCAGTTCGTTTG  
CGGTGACCGTGGTTTCTACTTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCG  
TGCTCCGCAGACCGGTATCGTTGACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCG  
TCTGGAAATGTACTGCGCTCCGCTGAAACCGGCTAAATCCGCTTAA

**FIG. 40**

37/38

Y. Mini-dsbA (3' modified)-hubi(del45).IGF.new  
Plasmid 25499

ATGGCGCA GTATGAAGAT GGTAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCTTCTGGTTCTTTCATGGGT GGTGACCTGG GCAAAGATCT  
GACTCAGGCA TGGGCTGTGG CGATGGCGCT GGGCGTGGA GACAAAGTGA  
CTGTTCCGCT GTTTGAAGGC GTACAGAAAA CCCAGACCAT TCGTTCCTGCT  
TCTGATATCC GCGATGTATT TATCAACGCA GGTATTAAAG GTGAAGAGTA  
CGACGCGGCG TGGAACAGCT TCGTGGTGAA ATCTCTGGTC GCTCAGCAGG  
AAAAAGCTGC AGCTGACGTG CAATTGCGTG GCGTTCGGC GATGTTTGTT  
AACGGTAAAT ATCAGCTGAA TCCGCAGGGT ATGGATACCA GCAATATGGA  
TGTTTTTGTT CAGCAGTATG CTGATACAGT GAAATATCTG TCCGAGAAAA  
AACATCATCA CCATCATCAC  
AGCATGCCCCGGAAGCAGCTAGAAGACGGTAGAACGCTGTCTGATTACAACATTCAG  
AAGGAGTCCACCTTACATCTTGTGCTAAGGCTCCGCGGTGGTGGTCCGGAAACCCTG  
TGCGGTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGGTTTCTAC  
TTCAACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACCGGTATC  
GTTGACGAATGCTGCTTCCGGTCTGCGACCTGCGTCGTCTGGAAATGTACTGCGCT  
CCGCTGAAACCGGCTAAATCCGCTTAA

**FIG. 41**

38/38

Z. Leaderless mini-dsBA (3' modified)-hubi.IGF.new  
Plasmid 25485 (vector pUC18)

ATGGCGCA GTATGAAGAT GGTAACAGT ACACTACCCT GGAAAAACCG  
GTAGCTGGCG CGCCTTCTGG TTCTTTCATG GGTGGTGACC TGGGCAAAGA  
TCT GACTCAGGCA TGGGCTGTGG CGATGGCGCT GGGCGTGGA  
GACAAAGTGA CTGTTCCGCT GTTTGAAGGC GTACAGAAAA CCCAGACCAT  
TCGTTCTGCT TCTGATATCC GCGATGTATT TATCAACGCA GGTATTAAAG  
GTGAAGAGTA CGACGCGGCG TGGAACAGCT TCGTGGTGAA ATCTCTGGTC  
GCTCAGCAGG AAAAAGCTGC AGCTGACGTG CAATTGCGTG GCGTTCCGGC  
GATGTTTGT T AACGGTAAAT ATCAGCTGAA TCCGCAGGGT ATGGATACCA  
GCAATATGGA TGTTTTTGT CAGCAGTATG CTGATACAGT GAAATATCTG  
TCCGAGAAAA AACATCATCA CCATCATCAC AGCATGCAGATTTTCGTCAAGA  
CTTTGACCGGTAAAACCATAACATTGGAAGTTGAACCTTCCGATACCATCGAGAACG  
TTAAGGCGAAAATTCAAGACAAGGAAGGTATCCCTCCAGATCAACAAAGATTGATCT  
TTGCCGGAAGCAGCTAGAAGACGGTAGAACGCTGTCTGATTACAACATTAGAAGG  
AGTCCACCTTACATCTTGTGCTAAGGCTCCGCGGTGGTGGTCCGGAACCCCTGTGCG  
GTGCTGAACTGGTTGACGCTCTTCAGTTCGTTTGCGGTGACCGTGTTTCTACTTCA  
ACAAACCGACCGGTTACGGTTCCTCCTCCCGTCGTGCTCCGCAGACCGGTATCGTTG  
ACGAATGCTGCTTCCGGTCCTGCGACCTGCGTCGTCTGGAAATGTACTGCGCTCCGC  
TGAAACCGGCTAAATCCGCTTAA

FIG. 42



**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07K 14/705; C12N 15/62

US CL : 435/69.7, 252.3, 320.1; 530/350, 351; 536/23.4, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7, 252.3, 320.1; 530/350, 351; 536/23.4, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: interleukin, DbA, (fusion# or hybrid# or chimera?)(2a)(protein# or gene#)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,595,658 (ZINDER ET AL) 17 JUNE 1986, col. 2, line 46 to col. 3, line 9 and col. 4, lines 30 to 49.	1-5, 7-9, 11, 12, 14, 15, 17-25, 27-29, 31-34, 36, 37, 39, 40, 42, 43.
Y	CELL, Vol. 67, issued 01 November 1991, C. A. Bardwell et al, "Identification of a Protein Required for Disulfide Bond Formation In Vivo", pages 581-589, see entire document.	1-5, 7-9, 11, 12, 14, 15, 17-25, 27-29, 31-34, 36, 37, 39, 40, 42, 43.

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 OCTOBER 1994

Date of mailing of the international search report

16 NOV 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN D. ULM

Telephone No. (703) 308-0196

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Biological Chemistry, Vol. 266, No. 18, issued 25 June 1991, J. W. Tobias et al, "Cloning and Functional Analysis of the Ubiquitin-specific Protease Gene <i>UBP 1</i> of <i>Saccharomyces cerevisiae</i> ", pages 12021-12028, see entire document.	1-5, 7-9, 11, 12, 14, 15, 17-25, 27-29, 31-34, 36, 37, 39, 40, 42, 43.
Y	BIO/TECHNOLOGY, Vol. 11, issued February 1993, E. R. LaVallie et al, "A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the <i>E. coli</i> Cytoplasm", pages 187-193, see entire document.	1-5, 7-9, 11, 12, 14, 15, 17-25, 27-29, 31-34, 36, 37, 39, 40, 42, 43.